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Liver X Receptor cis-Repression and Cholesterol Efflux Restrain 
Innate Immunity and Coronary Artery Disease 
 
David G. Thomas 
 
Atherosclerotic cardiovascular disease secondary to deposition of apolipoprotein B-containing 
lipoproteins in the artery wall is a leading cause of mortality. Therapies that reduce serum levels 
of atherogenic lipoprotein-cholesterol have been successful in reducing cardiovascular mortality, 
but this approach requires long-term treatment and substantial residual risk remains. Here, we 
investigate mechanistic determinants of atherosclerosis protection by two potential therapeutic 
approaches for lowering of residual cardiovascular risk. Using mouse models, we show that the 
nuclear receptor liver X receptor exerts an anti-inflammatory activity on innate immunity and 
atherosclerosis through both promotion of cholesterol efflux and a direct cis-repressive activity 
affecting neutrophil inflammation. We then assess the causal role of the cholesterol efflux pathway 
in human cardiovascular events by using genetic variants that modify high density lipoprotein-
cholesterol in instrumental variable analysis. We show that this pathway is associated with 
protection from cardiovascular disease in a precise and robust Mendelian randomization analysis 
on an FDR-controlled set of variants, which suggests a causal effect. Thus, agents that target the 
cholesterol efflux and liver X receptor cis-repression pathways may be protective in 
atherosclerosis.   
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Epidemiology and Treatment of Atherosclerosis 
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United 
States, accounting for 28% of overall mortality (Xu et al., 2018). ASCVD has several major 
manifestations, including coronary artery disease (CAD), ischemic stroke, and peripheral artery 
disease. These diseases share a common pathology involving cholesterol-rich arterial lesions 
that trigger inflammation and thrombosis, leading to tissue ischemia (Moore and Tabas, 2011). 
Key risk factors for ASCVD include age, sex, hypertension, diabetes, smoking, body mass index, 
and levels of serum lipids including low-density lipoprotein-cholesterol (LDL-C), high-density 
lipoprotein-cholesterol (HDL-C) and triglycerides (TG) (Herrington et al., 2016).  
 
Current therapies for prevention of ASCVD events focus on controlling risk factors, including LDL-
C, and on inhibition of thrombosis (Amsterdam et al., 2014). Anti-platelet strategies that inhibit 
atherothrombosis are efficacious but limited by bleeding complications, especially in primary 
prevention (Gaziano et al., 2018). Control of hypertension, diabetes, obesity, and smoking status 
by pharmacological and lifestyle interventions is beneficial in ASCVD prevention, although 
ischemic event rates in individuals without these risk factors remain substantial. Lowering LDL-C 
by statin drugs and the cholesterol absorption inhibitor ezetimibe has provided significant 
protection from atherothrombosis, especially in individuals at high risk of ASCVD (Baigent et al., 
2005; Cannon et al., 2015). Moreover, the low cost of these drugs makes their widespread use in 
high-risk populations practical, an important consideration as trends in population age and obesity 
underscore the need for scalable therapies for ASCVD.  
 
Recently, cardiovascular outcomes were reported for proprotein convertase subtilisin/kexin type 
9 (PCSK9) inhibitors, a new class of LDL-lowering monoclonal antibodies that decrease serum 
LDL by interfering with the degradation of the LDL receptor (Horton et al., 2007). Treatment with 
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PCSK9 inhibitors results in further ASCVD protection in statin-treated individuals (Sabatine et al., 
2017; Schwartz et al., 2018). However, substantial residual risk for atherothrombosis persists in 
individuals with effectively treated LDL-C (Fruchart et al., 2014). Moreover, LDL-lowering 
therapies are generally only fully effective in limiting atherothrombosis after more than one year 
of treatment (Bhatt et al., 2019; Cholesterol Treatment Trialists et al., 2010; Sabatine et al., 2017; 
Schwartz et al., 2018), an important limitation because CAD event risk is strongly increased in 
the period immediately following an initial CAD event.  
 
For these reasons, significant effort has been devoted to understanding the pathobiology of 
atherosclerosis and other points in this process distal to arterial cholesterol deposition. Relevant 
non-LDL targets include efflux of cholesterol from lesions to HDL and vascular inflammation 
(Ridker, 2016; Rosenson et al., 2012). The feasibility of anti-inflammatory, leukocyte-directed 
therapy for atherosclerosis was recently established by a phase III clinical trial of a neutralizing 
antibody for the pro-inflammatory cytokine IL-1b, which demonstrated efficacy in prevention of 
CAD events (Ridker et al., 2017). However, the degree of absolute risk reduction was low and the 
treatment was associated with a significant increase in fatal infections. Thus, further 
understanding of the inflammatory pathways activated by lipid retention in the arterial wall may 
help in the design of anti-inflammatory therapies with greater efficacy and less risk of immune-
compromise.  
 
In parallel, efforts to suppress atherosclerosis by intervening on other lipid risk factors have had 
limited success. Clinical trials of agents that reduce TG or increase HDL-C, such as fibrates and 
niacin, have been mostly unsuccessful in reducing ischemic events and cardiovascular mortality 
(Accord Study Group et al., 2010; Aim-High Investigators et al., 2011; Hps Thrive Collaborative 
Group et al., 2014). Treatment with the TG-lowering agent icosapent ethyl reduced ASCVD 
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events by 25% in individuals with high TG in a recent trial, although the protective effect was 
observed regardless of whether effective TG-lowering was achieved (Bhatt et al., 2019). Several 
recent trials have assessed the potential for cardiovascular risk reduction by inhibition of the 
cholesteryl ester transfer protein (CETP). Three of these trials were unsuccessful despite effective 
elevation of HDL-C, in part due to concomitant blood pressure elevation (Barter et al., 2007; 
Lincoff et al., 2017; Schwartz et al., 2012). Treatment with a fourth CETP inhibitor, anacetrapib, 
increased HDL-C and decreased LDL-C, and was associated with reduced risk for CAD events 
(Hps Timi Reveal Collaborative Group et al., 2017). This was the largest trial of a CETP inhibitor 
and the first to go to completion. However, anacetrapib accumulated in adipose tissue and the 
degree of risk reduction was low, limiting potential for commercialization of this drug. Moreover, 
although HDL-C levels were markedly increased by anacetrapib, the cholesterol efflux capacity 
of HDL, which appears to be a key anti-atherogenic function, was only modestly increased by the 
combination of anacetrapib and statin, and it is unclear if the beneficial effect on CAD risk was 
related to LDL-C reduction or HDL-C elevation (Tall and Rader, 2018). 
 
Alternatively, HDL function may be augmented by infusion of cholesterol-poor reconstituted HDL 
(rHDL), which increases HDL-C levels and markedly increases cholesterol efflux capacity. rHDL 
infusions appear to be safe, and two such preparations, MDCO-216 and CER-001, have been 
tested with the goal of reducing coronary atherosclerotic plaque burden measured by 
intravascular ultrasound in short-term serial imaging studies (Nicholls et al., 2018a; Nicholls et al., 
2018b). Neither rHDL particle succeeded in reducing plaque burden by imaging, although 
treatment led to only modest increases in measures of HDL biomarkers, including serum 
apolipoprotein A-I (ApoAI), HDL-C, and cholesterol efflux capacity, suggesting that the dose may 
have been insufficient (Rader, 2018). A third rHDL product, CSL-112, has been developed that 
has large effects on HDL-C and cholesterol efflux capacity (Gille et al., 2018), and it will be tested 
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for prevention of recurrent CAD events after acute coronary syndrome in an ongoing phase III 
clinical trial (AEGIS-II, NCT03473223). 
 
Thus, LDL-lowering remains the mainstay of treatment for atherosclerosis, while approaches 
directed at inflammation and cholesterol efflux remain promising for future therapeutic 
development. In the following sections, we discuss activation of liver X receptor (LXR) as a 
therapeutic approach with beneficial effects on both cholesterol efflux and inflammation and 
critically appraise evidence for the causal contribution of HDL-C in atherosclerosis. The 
subsequent chapters establish the mechanism for the anti-inflammatory activity of LXR and 
provide genetic evidence for a causal association between HDL-C and CAD risk.  
 
Cell Biology of Atherosclerosis 
Atherosclerosis is initiated by the retention of cholesterol-rich, apolipoprotein B (apoB)-containing 
lipoproteins, including LDL, in the artery wall (Williams and Tabas, 1995). Subendothelial lipid 
accumulation leads to an inflammatory reaction that stimulates the recruitment of monocytes and 
their differentiation into macrophages (Moore and Tabas, 2011). Lesional macrophages 
metabolize the lipid burden of the atheroma by several mechanisms, including oxidation of fatty 
acids and efflux of cholesterol to HDL. HDL particles accept lesional cholesterol, which cannot be 
broken down in situ, and transport cholesterol to the liver where it can be excreted in the bile in a 
process called reverse cholesterol transport (RCT; Figure 1.1) (Rosenson et al., 2012). 
Macrophages transfer cholesterol to HDL principally through the cholesterol efflux transporters 
ATP-dependent cassette transporter A1 and G1 (ABCA1/ABCG1) (Wang et al., 2007). Thus, 
many atherosclerotic lesions are stabilized or resolved without incident, as underscored by the 




adults in autopsy studies despite the lack of clinical manifestations of ASCVD in this population 
(McMahan et al., 2006).  
 
Macrophages that accumulate cholesterol in atherosclerotic lesions store it primarily in cholesteryl 
esters in lipid droplets and become foam cells (Moore and Tabas, 2011). Nevertheless, sustained 
cholesterol loading leads to free cholesterol accumulation and ER stress, leading to apoptosis of 
foam cells and secondary necrosis if apoptotic cell corpses are not rapidly cleared (Seimon and 
Tabas, 2009). Secondary necrosis leads to the release of damage-associated molecular patterns, 
such as oxidized phospholipids, DNA, and nuclear proteins, which activate pattern recognition 
receptors including the Toll-like receptors (TLRs) and promote inflammation and autoimmunity 
(Sachet et al., 2017). In addition, oxidatively modified lipoproteins and cholesterol crystals activate 
sensors of damage-associated molecular patterns such as CD36-TLR4/6 complexes and the 
NLRP3 inflammasome, respectively (Duewell et al., 2010; Que et al., 2018; Stewart et al., 2010). 
 
Cholesterol accumulation in lesional macrophages leads to increased free cholesterol in the 
plasma membrane, which exacerbates inflammatory signaling through TLRs. Macrophages from 
ABCA1/ABCG1 knockout mice (ABCDKO) have increased plasma membrane cholesterol, 
increased expression of TLR4, and increased inflammatory gene expression after stimulation of 
TLRs (Yvan-Charvet et al., 2008). Consequently, hyperlipidemic ABCDKO bone marrow recipients 
have increased atherosclerosis and myeloid-specific ABCDKO mice have exacerbated 
atherosclerotic lesion progression relative to their level of hypercholesterolemia (Westerterp et 
al., 2013; Yvan-Charvet et al., 2007).  
 
The progression of inflammation in lesional macrophages leads to the recruitment of other 
inflammatory leukocytes, including neutrophils, monocyte-derived macrophages that escape lipid-
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loading, and cells of the adaptive immune system. Studies utilizing experimental induction of 
neutrophilia or neutropenia in mice suggest that neutrophils play a role in the progression of early 
atherosclerosis (Drechsler et al., 2010; Zernecke et al., 2008). Neutrophils are not abundant in 
atherosclerotic lesions from hyperlipidemic mice under normal conditions but are abundant in 
myeloid-specific ABCDKO mice, which have defective macrophage and neutrophil cholesterol 
efflux pathways (Westerterp et al., 2018). In this background, lesional neutrophils extrude their 
chromatin to form neutrophil extracellular traps rich in damage-associated molecular patterns. In 
another line of experiments, single cell transcriptomic analysis has revealed a distinct population 
of lesional monocyte-derived macrophages that do not accumulate lipids but instead play 
important roles in inflammatory signal integration and cytokine production (Kim et al., 2018).  
 
Adaptive immune cells including T cells and B cells play a distinct but more circumscribed role in 
the progression of atherosclerosis. Mice without recombination activating gene 1 (Rag1-/-) lack 
mature lymphocytes, and hyperlipidemic Rag1-/- mice have only minor differences in 
atherosclerotic lesion progression (Dansky et al., 1997; Song et al., 2001). In contrast, depletion 
of circulating monocytes can be accomplished by deletion of the macrophage/monocyte 
differentiation factor colony stimulating factor 1 (Csf1-/-) and hyperlipidemic Csf1-/- mice have 
almost no atherosclerosis (Smith et al., 1995). Nevertheless, T cells are the primary cellular 
source of interferon-gamma (IFNγ), and hyperlipidemic Ifng-/- mice are protected from 
atherosclerosis (Gupta et al., 1997). Regulatory T cells also play a role in atherosclerosis (Ait-
Oufella et al., 2006; Subramanian et al., 2013), although these cells may lose their 















































Role of LXR in Atherosclerosis 
The liver X receptor (LXR) is a nuclear receptor with two isoforms, LXRα and LXRβ, that bind to 
a response element containing a direct repeat of AGGTCA nuclear receptor half-sites with a 4-
nucleotide spacer (Teboul et al., 1995; Willy et al., 1995). Several oxidized cholesterol species 
activate LXR at physiologic concentrations (Janowski et al., 1996), and it has been proposed that 
LXR is activated during cellular cholesterol accumulation by the cholesterol biosynthesis 
intermediate desmosterol (Spann et al., 2012). However, other oxidized metabolites of cholesterol 
may mediate LXR activation in other settings, such as inflammation and efferocytosis (Kiss et al., 
2006).  
 
Clinical interest in LXR was stimulated by the discovery that LXR activation induces expression 
of ABCA1, which mediates cholesterol transport to lipid-poor ApoAI (Costet et al., 2000; Repa et 
al., 2000b). LXR was also found to stimulate ABCA1-independent cholesterol efflux to mature 
HDL particles, and this activity was attributed to ABCG1 (Wang et al., 2004). Thus, LXR activates 
multiple pathways that support cholesterol efflux to HDL, suggesting that LXR activation might 
promote the resolution of atherosclerotic lesions by reverse cholesterol transport. Indeed, LXR 
knockout in bone marrow-derived cells strongly aggravates atherosclerosis (Tangirala et al., 
2002). However, LXR also supports hepatic expression of the lipogenic transcription factor 
Srebf1, leading to hypertriglyceridemia and fatty liver when hepatic LXR is activated (Repa et al., 
2000a; Schultz et al., 2000).  
 
Nevertheless, pharmacological agonists of LXR have been developed, including the compounds 
T0901317 and GW3965, and these agonists potently suppress atherogenesis in hyperlipidemic 
mouse models (Joseph et al., 2002b; Terasaka et al., 2003). This activity is accompanied by 
induction of cholesterol efflux transporters in the aorta, and LXR agonist treatment increases 
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reverse cholesterol transport measured by radiolabeled macrophage-to-feces or macrophage-to-
plasma cholesterol transfer (Joseph et al., 2002b; Naik et al., 2006). Moreover, the anti-
atherogenic activity of T0901317 is ablated in hyperlipidemic LXR-deficient bone marrow 
recipients, suggesting a key role for macrophage LXR in the effect of LXR agonists (Levin et al., 
2005). These studies suggested that the potent anti-atherogenic activity of LXR agonists is 
mediated at least in part by cholesterol removal from atherosclerotic lesions.  
 
However, recent studies have strongly challenged the notion that the LXR’s anti-atherogenic 
activity is completely dependent on stimulation of cholesterol efflux from lesional macrophages. 
ABCDKO macrophages have almost no LXR-dependent cholesterol efflux (Westerterp et al., 2013), 
but LXR agonists still suppress atherosclerosis in hyperlipidemic mice with bone marrow from 
ABCDKO knockout mice or from myeloid-specific ABCDKO knockout mice (Kappus et al., 2014). In 
liver-specific LXR knockout mice, LXR agonists no longer increase RCT but still suppress 
atherosclerosis (Zhang et al., 2012). Thus, several lines of evidence support additional beneficial 
activities of LXR in atherosclerosis beyond promotion of cholesterol efflux, and it has been 
proposed that other LXR targets may play a role in protection from atherosclerosis by LXR 
(Schulman, 2017).  
 
In addition to cholesterol efflux transporters, LXR transcriptionally activates a well-defined set of 
genes related to fatty acid metabolism, which may modulate macrophage inflammatory signaling 
by altering plasma membrane composition (Ito et al., 2015; Schulman, 2017). LXR directly 
induces several genes involved in fatty acid metabolism in addition to Srebf1, including fatty acid 
synthase (Fasn) (Joseph et al., 2002a), stearoyl-CoA desaturase 1 and 2 (Scd1/2) (Chu et al., 
2006; Spann et al., 2012), fatty acid elongase 5 (Elovl5) (Varin et al., 2015), acyl-CoA synthetase 
3 and 4 (Ascl3/4) (Varin et al., 2015), and lysophosphatidylcholine acyltransferase 3 (Lpcat3) 
11 
 
(Rong et al., 2013). These enzymes all function in the biosynthetic pathway for production of 
unsaturated fatty acids, which decrease cholesterol toxicity both by decreasing membrane order 
and by acting as substrates for cholesterol esterification.  
 
Other LXR targets have recently described roles in regulation of cholesterol homeostasis, 
including the LDLR-degrading ubiquitin E3 ligase gene Idol (Zelcer et al., 2009), the ABCA1-
regulatory gene Eepd1 (Nelson et al., 2017b), the SCAP-degrading ubiquitin E3 ligase gene 
Rnf145 (Zhang et al., 2017), and the cholesterol trafficking gene Gramd1b (Sandhu et al., 2018). 
LXR also supports the expression of the efferocytosis receptor gene Mertk (A-Gonzalez et al., 
2009); MERTK promotes cholesterol loading and LXR activation in the setting of inflammation 
resolution by facilitating the uptake of cholesterol-rich apoptotic cell corpses (Kiss et al., 2006).  
 
Anti-Inflammatory Activity of LXR 
LXR agonists are potently anti-inflammatory, like agonists of the glucocorticoid receptor, 
peroxisome proliferator-activated receptor gamma (PPARγ), and several other nuclear receptors 
(Barnes, 1998; Castrillo et al., 2003; Ricote et al., 1998). Treatment with the LXR agonist GW3965 
or T0901317 in macrophages represses inflammatory genes, including Cox2, Il1b, Nos2, and Tnf, 
in an LXR-dependent manner (Joseph et al., 2003). Treatment with GW3965, T0901317, or an 
oxysterol agonist of LXR reduces inflammatory mediator expression in keratinocytes and 
leukocyte infiltration in a mouse model of contact dermatitis, and these effects are abrogated by 
LXR knockout (Fowler et al., 2003; Joseph et al., 2003). Subsequent studies generally support a 
protective effect of LXR activation in inflammatory and autoimmune diseases, including 
experimental colitis, arthritis, and lupus, although the specificity of LXR agonist effects is not well-




In experimental colitis, knockout of LXRα, LXRβ, or LXRα/LXRβ leads to increased weight loss, 
diarrhea, bleeding, and decreased survival when the colonic epithelium is disrupted by dextran 
sodium sulfate (Jakobsson et al., 2014). In this model, LXR deficiency increases expression of 
inflammatory mediators and leukocyte recruitment. Moreover, expression of LXRα and LXRβ are 
reduced in human inflammatory bowel disease (Jakobsson et al., 2014). The synthetic LXR 
agonist GW3965 attenuates inflammation and weight loss in experimental colitis, and sterol-
based LXR agonists achieve these effects without stimulating hepatic lipogenesis (Jakobsson et 
al., 2014; Yu et al., 2016), suggesting a pharmacological strategy for translation of these effects.  
 
Treatment with the LXR agonist GW3965 reduces expression of Cox2, Il1b, Nos2, and Tnf in 
murine collagen-induced arthritis (Park et al., 2010). In this model, GW3965 treatment reduces 
incidence of arthritis, clinical score, and histological damage. In a similar manner, treatment with 
GW3965 in an osteoarthritis explant model reduces expression of Cox2 and cartilage 
degradation, which is exacerbated by LXRβ deficiency (Li et al., 2010). However, another study 
reported increased inflammatory mediator production and arthritis incidence and severity after 
GW3965 or T091317 treatment in the collagen-induced arthritis model (Asquith et al., 2009). 
Thus, LXR agonists may be beneficial in rheumatoid arthritis and osteoarthritis, but further study 
is required to determine the scope of paradoxical pro-inflammatory effects.  
 
LXRα/LXRβ knockout mice have age-dependent autoimmunity which is prominent at 10 months 
of age and leads to splenomegaly and glomerulonephritis with dsDNA antibodies, reproducing 
several features of systemic lupus erythematosus (A-Gonzalez et al., 2009). This autoimmune 
syndrome was attributed to delayed apoptotic cell clearance in LXR-deficient mice, like the 
phenotype of mice deficient in the LXR target MERTK (Cohen et al., 2002). MERTK prevents 
autoimmunity by clearing apoptotic cells before the onset of secondary necrosis, which is 
13 
 
associated with the production of autoantigens. Dendritic cell-specific ABCDKO mice also have an 
autoimmune phenotype associated with increased cholesterol accumulation, inflammasome 
activation, and cytokine production in dendritic cells, which also leads to lymphadenopathy and 
glomerulonephritis, suggesting that these LXR targets play a key role in suppression of 
autoimmunity (Westerterp et al., 2017). In the B6lpr/lpr model of experimental lupus, deletion of self-
reactive T cells is impaired, resulting in lymphadenopathy and glomerulonephritis, and these 
phenotypes are suppressed by treatment with the LXR agonist GW3965 (A-Gonzalez et al., 
2009).  
 
LXR regulates adaptive immunity through effects in T cells and dendritic cells, which may 
contribute to the efficacy of LXR agonists in the lupus model. In T cells, T cell receptor signaling 
suppresses LXR-dependent, ABCG1-mediated cholesterol efflux by inducing the oxysterol-
metabolizing gene SULT2B1 (Bensinger et al., 2008). The accumulation of membrane cholesterol 
in T cells enhances T cell proliferation by increasing signaling through the T cell receptor, which 
directly binds cholesterol (Armstrong et al., 2010). Knockout of LXRβ in hypercholesterolemic 
mice promotes autoimmunity through a mechanism that involves increased T cell stimulation by 
dendritic cells and increased T cell proliferation (Ito et al., 2016). On the other hand, LXR 
activation in mouse and human dendritic cells in vitro is paradoxically pro-inflammatory and 
promotes inflammatory gene expression and cell migration (Beceiro et al., 2018; Torocsik et al., 
2010).  
 
LXRα/LXRβ knockout mice have altered antibacterial immunity, with resistance to tuberculosis 
and susceptibility to Listeria monocytogenes, although the basis for these differential effects may 
be pathogen-specific (Joseph et al., 2004; Korf et al., 2009). LXR activation suppresses neutrophil 
recruitment in a model of bacterial pneumonia and in sterile inflammation of the lung, and LXR is 
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well-expressed in neutrophils (Smoak et al., 2008). This study also showed that the LXR agonist 
T0901317 suppresses neutrophil migration in in vitro assays of chemokine-directed migration, 
consistent with a cell-intrinsic effect in neutrophils. In some studies, treatment with LXR agonists 
leads to a decrease in circulating neutrophils, including in a recent phase I clinical trial (Hong et 
al., 2012; Kirchgessner et al., 2016); in other studies, there is no neutropenic effect, including 
another phase I clinical trial (Kappus et al., 2014; Smoak et al., 2008; Tavazoie et al., 2018). Thus, 
LXR activation suppresses chemokine-directed neutrophil migration, while effects on neutrophil 
counts may be agonist- or model-specific.  
 
Despite promising results from preclinical models, efforts to characterize the effect of LXR 
agonists on inflammatory gene expression in human cells have been less robust. A study of 
peripheral blood mononuclear cell-derived macrophages showed that the LXR agonist GW3965 
or T0901317 represses inflammatory gene expression during short-term treatment but 
potentiated TLR4-dependent inflammation in long-term treatment (Fontaine et al., 2007). The 
mechanism for this effect was attributed to direct induction of the Tlr4 gene by LXR, which is 
consistent with gene expression results in other studies on human cells (Nelson et al., 2017b; 
Traini et al., 2014). However, several other studies have reported anti-inflammatory effects of LXR 
agonists GW3965 and T0901317 with short- or long-term treatment, including repression of the 
human Cox2 and Il1b genes, using the THP1 human monocyte/macrophage cell line and human 
primary lung macrophages (Birrell et al., 2007; Traini et al., 2014). Loss-of-function models for 
human LXR could be highly informative in clarifying these conflicting results. Thus, the anti-





In general, the study of LXR’s anti-inflammatory effects is complicated by the multiplicity of 
functions of LXR in metabolism and inflammation in different cells of the immune system. These 
effects make it difficult to assess specific effects of LXR in LXR knockout mice, particularly due to 
the onset of frank autoimmunity with age or hypercholesterolemia. LXR agonist studies have 
partially bridged this gap by permitting the assessment of LXR activation phenotypes in isolated 
cells in vitro, but this strategy is limited in many cases by the off-target effects of currently available 
agonists. The development of tissue-specific and inducible LXRα/LXRβ knockout mice with LXR 
deficiency in different immune cell types will be essential for detailed understanding of LXR 
functions in inflammation and immunity.  
 
Proposed Mechanisms of LXR Repression 
While the mechanism of LXR transactivation at LXR targets is well-established, the mechanism 
of inflammatory gene repression by LXR remains controversial (Fessler, 2018; Schulman, 2017). 
Early clues to the mechanism of LXR repression of inflammatory genes came from the finding 
that unliganded LXR represses a subset of LXR targets. Studies of LXR target expression in LXR 
knockout mice revealed that unliganded LXR represses certain LXR targets, such as Abca1, by 
recruiting the nuclear receptor corepressor (NCoR) in a promoter- and tissue-specific manner 
(Wagner et al., 2003). On the other hand, other LXR targets like Srebf1 were found to have 
decreased expression in LXR knockout mice, suggesting that LXR supports basal expression of 
these targets (Repa et al., 2000a). This pattern of regulation suggested that promoter-specific 
and lineage-associated transcription factors modify LXR’s repressive capacity.  
 
Based on this basal repression mechanism and similar interactions that had been described for 
the nuclear receptor PPARγ, it was proposed that the anti-inflammatory LXR repression pathway 
co-opts the LXR-NCoR interaction to suppress inflammatory gene expression in hepatocytes 
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(Blaschke et al., 2006; Pascual et al., 2005). This model suggested that LXR activation interferes 
with NCoR clearance during stimulus-dependent transcriptional activation of inflammatory genes 
(Figure 1.2). In line with this concept, several laboratories observed LXR binding by chromatin 
immunoprecipitation assays at inflammatory gene promoters in primary macrophages and 
hepatocytes (Ghisletti et al., 2007; Venteclef et al., 2010).  
 
Subsequent studies defined a pathway in which liganded LXR is post-translationally modified by 
addition of a Small Ubiquitin-like Modifier (SUMO) group, which confers NCoR binding affinity 
even in the liganded state (Ghisletti et al., 2007; Huang et al., 2011). A key limitation of these 
studies is that assays for SUMOylation of LXR in primary cells are not available. Consequently, 
evidence for LXR SUMOylation is limited to overexpression co-immunoprecipitation experiments 
and functional studies in immortalized macrophage-like cell lines. Nevertheless, a mechanism for 
LXR interference with corepressor clearance was defined, in which SUMOylated LXR has affinity 
for the NCoR- and actin-interacting protein coronin 2A and blocks its role in turnover of 
corepressor complexes (Huang et al., 2011). This model suggests that LXR binds indirectly to 
inflammatory gene promoters via pre-associated NCoR complexes recruited to nuclear factor κB 
(NF-κB) or activator protein- 1 (AP-1) response elements, but does not specify a role for the DNA-
binding domain of LXR (Glass and Saijo, 2010). Thus, a conceptual limitation of this model is that 
it does not provide an explanation for the specificity of LXR’s anti-inflammatory effect.  
 
SUMOylation of LXR appears to resolve the important question of how liganded LXR retains 
affinity for NCoR, but it may be an oversimplification to suggest that LXR either binds NCoR or 
releases NCoR depending on the availability of LXR ligand. Studies on repression by unliganded 
LXR show that chromatin context may play a key role in modulating LXR’s affinity for corepressors 
or coactivators (Wagner et al., 2003). Furthermore, a specific inverse agonist for LXR has been 
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developed that stabilizes the LXR-NCoR interaction (Griffett et al., 2013). Treatment of 
unstimulated primary macrophages with this inverse agonist leads to Abca1 repression in the 
absence of ligand, e.g. in a state in which LXR is already competent to bind NCoR (our 
unpublished data). Thus, LXR agonist and antagonists shift the equilibrium between LXR-
corepressor and LXR-coactivator interactions in a nonbinary and chromatin context-dependent 
manner.  
 
More generally, the LXR SUMOylation hypothesis has been tested by loss-of-function models for 
NCoR, with mixed results. NCoR knockout causes prenatal lethality in mice, but NCoR-deficient 
fetal liver hematopoietic precursors were isolated and differentiated into macrophages, which lack 
LXR repression upon LXR agonist treatment (Ghisletti et al., 2009). Mice with myeloid NCoR 
deficiency were subsequently generated and have improved insulin sensitivity after high-fat diet 
feeding (Li et al., 2013). In this setting, NCoR knockout leads to reduced inflammatory gene 
expression in macrophages, in contradistinction to the prediction of the LXR SUMOylation 
hypothesis, which holds that NCoR is a key repressor of inflammatory genes. This anti-
inflammatory activity is associated with reduced deposition of activating histone marks at 
inflammatory genes, but NF-κB binding at inflammatory gene promoters is intact.  
 
Moreover, NCoR knockout in macrophages leads to induction of several LXR targets, including 
Abca1 and the fatty acid desaturation genes Scd2, Elovl5, and Fads2. Thus, it was reported that 
the primary effect of macrophage NCoR knockout may be metabolic gene derepression, which 
leads to inflammatory gene repression through interference with inflammatory signaling by 
metabolic activities of LXR targets, including unsaturated fatty acid biosynthesis (Li et al., 2013). 
However, subsequent studies with LXR knockout macrophages showed that LXR is dispensable 
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for the synthesis of immunomodulatory unsaturated fatty acids in inflammatory macrophages, 
which is mediated by SREBP1 (Oishi et al., 2017).  
 
A subsequent report suggested that ABCA1 is the sole mediator of LXR’s anti-inflammatory 
function in macrophages (Ito et al., 2015). This study used immortalized bone marrow-derived 
macrophages to circumvent the requirement for cell lines in genetic analysis of LXR repression. 
In immortalized macrophages with LXR’s putative SUMOylation sites mutated, the repressive 
effects of LXR agonists remain robust. Moreover, in macrophages cultured under sterol-depleted 
conditions, knockout or knockdown of ABCA1 attenuates most anti-inflammatory effects of LXR 
agonists (Ito et al., 2015). In this setting, upregulation of ABCA1 by LXR activation leads to 
decreased cholesterol content, reducing membrane order and lipid raft-dependent signaling 
events. Consequently, signaling from TLR4 to its adaptor protein MYD88 is reduced, suppressing 
the activation of NF-κB and AP-1 (Ito et al., 2015). Thus, cholesterol depletion after LXR activation 
may itself account for LXR repression. On the other hand, a previous study using ABCDKO 
macrophages showed that LXR agonist treatment leads to inflammatory gene repression in these 
cells, which lack LXR-dependent cholesterol efflux (Kappus et al., 2014).  
 
Anti-inflammatory activities of LXR targets other than ABCA1 and fatty acid desaturase enzymes 
have also been described, including for the LXR target LPCAT3. LPCAT3 adds a fatty acid to the 
sn-2 position of lysophosphatidylcholine to generate phosphatidylcholine and strongly favors 
polyunsaturated fatty acids as substrates for this reaction. Consequently, deficiency of LPCAT3 
leads to decreased polyunsaturated fatty incorporation in phosphatidylcholine (Rong et al., 2013). 
It has been proposed that this defect decreases membrane order and TLR4 signaling. Hepatic 
knockdown of Lpcat3 exacerbates metabolic inflammation in mice, and knockdown of Lpcat3 in 
primary macrophages reverses some repressive effects of LXR agonists (Rong et al., 2013). 
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However, another study found that LPCAT3 expression is dispensable for LXR repression in 
primary mouse macrophages and showed that LPCAT3 activity leads to increased membrane 
arachidonic acid content and increased inflammatory mediator production in human macrophages 
(Ishibashi et al., 2013). Thus, the role of LPCAT3 in LXR repression is unclear.  
 
The LXR target MERTK also suppresses inflammatory signaling in certain settings, both by 
mediating uptake of apoptotic cells that carry anti-inflammatory molecules and by signaling 
through its tyrosine kinase intracellular domain (Camenisch et al., 1999; Rothlin et al., 2007). 
Consequently, it has been suggested that MERTK may play a role in the anti-inflammatory 
function of LXR (Fessler, 2018). However, the requirement for MERTK in inflammatory gene 
repression by LXR agonists in macrophages has not been directly assessed.  
 
In summary, while recent studies have implicated direct repressive effects or LXR target effects 
in the anti-inflammatory function of LXR (Figure 1.2), the mechanistic determinants of LXR 
repression are not clearly established. The studies described in Chapter 2 delineate the 
contributions of key LXR targets to LXR repression of inflammatory genes and use unbiased, 
genome-wide approaches to unveil a direct cis-repressive activity of LXR. In vivo studies of LXR 
agonist effects in sterile inflammation connect this cis-repressive activity and LXR’s role in 
promoting cholesterol efflux to protective effects on neutrophil migration in peritonitis and 







































Figure 1.2 Previously proposed LXR target-dependent (1) and transrepression (2) mechanisms 






HDL-C and Protection from Atherosclerosis 
Although HDL-C is associated with protection from atherosclerosis in observational studies, and 
HDL function is linked to clearance of cholesterol from atherosclerotic lesions, the causal role of 
HDL in human CAD remains controversial. HDL function can be assessed by measurement of 
HDL cholesterol efflux capacity in an ex vivo assay, and high cholesterol efflux capacity is 
associated with decreased angiographic CAD and decreased risk of CAD events (Khera et al., 
2011; Rohatgi et al., 2014). Cholesterol efflux capacity correlates with HDL-C but is protective in 
CAD even when corrected for HDL-C, suggesting that HDL-C may be a marker of this causal 
protective pathway of cholesterol clearance. However, HDL-C is strongly inversely correlated with 
TG due to the activity of cholesteryl ester transport protein (CETP), which exchanges triglycerides 
from TG-rich lipoproteins with cholesterol on HDL (Inazu et al., 1990), and TG is associated with 
CAD event risk (Sarwar et al., 2007). Thus, it is unclear whether HDL-C is protective, TG is 
deleterious, or both associations are causal.  
 
Mechanistically, TG levels have been suggested to have adverse effects in atherosclerosis either 
directly by adverse effects on lesion progression (Nordestgaard, 2016), or indirectly by indicating 
the presence of atherogenic cholesterol in chylomicron remnants and VLDL, which are not 
included in LDL-C measurements (Varbo et al., 2013). As the latter effect is more well-
established, recent studies have quantified apoB-containing lipoprotein-associated risk by 
measuring non-HDL-C, representing LDL-C and remnant/VLDL-cholesterol, which is a stronger 
predictor of CAD risk than LDL-C alone (Boekholdt et al., 2012). HDL-C remains protective in 
CAD when risk is adjusted for non-HDL-C and TG levels, but TG is no longer associated with 
CAD after adjustment for non-HDL-C and HDL-C (Emerging Risk Factors et al., 2009). Thus, 
evidence from observational studies is consistent with a protective effect of HDL in CAD, with 
limited evidence for a role of TG independent of its role as a marker of TG-rich lipoprotein-
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cholesterol. Nevertheless, the potential for confounding in observational studies of HDL-C and 
TG associations with CAD risk limits their utility in causal inference.  
 
Rare monogenic disorders leading to very high or low HDL-C have provided some insight into 
their mechanisms in CAD. Homozygous loss-of-function mutations in ApoAI and ABCA1 strongly 
attenuate levels of circulating HDL and are associated with premature CAD in some cases 
(Ordovas et al., 1986; Serfaty-Lacrosniere et al., 1994). Lecithin-cholesterol acyltransferase 
deficiency leads to rapid catabolism of HDL particles and is associated with decreased LDL-C 
and HDL-C without premature CAD (Qasim and Rader, 2006; Schaefer, 1984). Scavenger 
receptor class B, type I (SR-BI) mediates clearance of HDL-C and mutations in SR-BI were 
recently found to increase HDL-C and CAD risk (Zanoni et al., 2016). However, other HDL-C-
raising variants in SR-BI are not associated with CAD risk (Helgadottir et al., 2018). Mutations in 
CETP strongly increase HDL-C and moderately decrease LDL-C and are associated with 
decreased CAD risk, although the risk reduction is modest (Inazu et al., 1990; Nomura et al., 
2017). In general, the heterogeneity in phenotypes and perturbation of the underlying metabolic 
process in monogenic disorders of HDL metabolism complicates inference of the causal 
associations between HDL-C and CAD.  
 
As an alternative strategy to decouple HDL-C and TG effects on CAD risk while eliminating the 
effect of nonheritable confounders, several recent studies have pursued a Mendelian 
randomization approach. In Mendelian randomization, a genetic variant associated with a lipid 
risk factor is used to partition a population in which CAD risk data is available, and the CAD effect 
related to the variant’s perturbation of lipid levels for each genotype is then assessed (Burgess et 
al., 2018). This design is advantageous in that it eliminates confounding by reverse causation, 
since variants are assigned prior to disease development, as well as confounding by nonheritable 
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exposures, e.g. lifestyle factors, since variants are assigned independently of these exposures. 
Power is reduced in Mendelian randomization compared to observational analysis, although 
power can be improved by using multiple variants to assess a risk factor-disease outcome 
association (Palmer et al., 2012). However, pleiotropic variants that affect the disease outcome 
via multiple mechanisms can distort the Mendelian randomization association and introduce bias, 
and moreover, genetic pleiotropy is widespread (Verbanck et al., 2018).  
 
In an early Mendelian randomization study on HDL-C in CAD, a single variant HDL-C-raising 
allele endothelial lipase gene or a 14-variant polygenic risk score associated with HDL-C had no 
effect on CAD risk (Voight et al., 2012). Later studies employed a more systematic multivariate 
Mendelian randomization approach that simultaneously accounted for effects of all three major 
lipid risk factors across all genome-wide significant lipid trait variants. This analysis suggested 
that LDL-C and TG are causally associated with CAD, while no causal association was detected 
for HDL-C (Do et al., 2013). However, this approach did not control for measurement error. One 
low-frequency variant, rs4332136, was measured in a very small number of individuals and was 
associated with a large HDL-C effect size and high measurement error. This variant was not 
associated with any effect on CAD risk and strongly influenced the HDL-C association. The variant 
rs4332136 was subsequently removed in a revision of the lipid genome-wide association study 
dataset due to the low number of measurements.  
 
Subsequently, an analysis of this data in which variants were weighted by measurement precision 
showed a causal association for HDL-C, as did analysis of a subset of variants lacking pleiotropic 
associations with blood pressure and body mass index (Burgess et al., 2014). A later study using 
a three-fold larger dataset of CAD events also detected a causal association for HDL-C, but this 
was attenuated when pleiotropic effects of lipid trait variants were modeled using the MR-EGGER 
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method (White et al., 2016). In MR-EGGER analysis, the association between HDL-C and CAD 
is modeled by fitting both the association coefficient representing the effect size, e.g. risk 
reduction per unit of HDL-C and an intercept representing the predicted effect on CAD in the 
absence of a change in HDL-C (Bowden et al., 2015). The intercept estimate represents the effect 
of modeled variants on CAD through HDL-C-independent mechanisms, or the global burden of 
pleiotropy in these variants, and fitting the model with the intercept adjusts the association 
coefficient for the effect of global pleiotropy. However, this method lacks precision compared to 
standard MR approaches (Zanetti et al., 2018), and it is unclear if this model is sufficiently 
powered to detect an HDL-C association.  
 
Nevertheless, the interpretation that Mendelian randomization indicates no causal association of 
HDL-C with CAD has broadly persisted in the atherosclerosis community (Benn and 
Nordestgaard, 2018; Dron and Hegele, 2016; McPherson and Tybjaerg-Hansen, 2016). In the 
Mendelian randomization field, the limitations of analysis on pleiotropic variants are now well-
appreciated and several statistical tools for pleiotropy detection have been developed (Verbanck 
et al., 2018). Thus, a key outstanding question is whether statistical approaches that account for 
the effects of pleiotropy while preserving statistical power and precision will detect an HDL-C 
association in large lipid trait and CAD datasets. The studies described in Chapter 3 use new 
instrumental variable selection and modeling approaches to increase power in pleiotropy-adjusted 
MR and reveal a causal association between HDL-C and CAD.  
 
Aims of the Thesis 
Therapeutic agents for atherosclerotic cardiovascular disease focus on controlling risk factors and 
preventing ischemic events in high-risk individuals. Novel therapies that act on existing 
atherosclerotic lesions to acutely reduce risk in individuals with proven cardiovascular disease 
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would effectively complement existing treatments. The present dissertation examines two 
strategies for acute stabilization of atherosclerotic lesions through the anti-inflammatory activity 
of the nuclear receptor LXR and cholesterol efflux to HDL. We hypothesize that a direct, cis-
repressive function of LXR and the reverse cholesterol transport function of HDL mediate 
protection from atherosclerosis.  
 
LXR activation has a well-established anti-atherogenic effect, but therapeutic development of LXR 
agonists is limited by hepatic toxicity. This toxicity might be circumvented by the design of targeted 
or selective LXR agonists if the protective effects of LXR were mechanistically well-defined, but 
recent studies have drawn conflicting and inconsistent conclusions regarding the molecular 
mechanisms of these effects. LXR agonists were developed as therapies for atherosclerosis 
based on their activity in promoting cholesterol efflux transporter expression, but retain anti-
atherogenic activity in cholesterol efflux transporter-deficient mice. Like several other nuclear 
receptors, LXR activation leads to potent suppression of inflammatory gene expression, and this 
activity has been attributed alternatively to either direct repression by LXR via a transrepression 
mechanism or the anti-inflammatory activities of LXR targets. However, mechanistic descriptions 
of LXR’s repressive activity have been inconsistent, and the link between specific anti-
inflammatory effects of LXR and the anti-atherogenic effects of LXR agonists is unclear.  
 
In parallel, protection from atherosclerosis by the HDL reverse cholesterol transport pathway has 
been called into question due to recent findings from genetic causality studies. These studies 
employ Mendelian randomization, which applies instrumental variable analysis to assess the 
causal contribution of cardiovascular risk factors to ischemic event risk using human genetic 
variants with measured effects on both the risk factor and event risk. In univariate and multivariate 
analyses of the effect of HDL-C genetic variants on CAD event risk, no causal protective effect 
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was observed, which has been interpreted as evidence that the observational protective 
association of HDL-C with CAD is due to confounding and no causal protective effect exists. On 
the other hand, the Mendelian randomization approach faces limitations in statistical power and 
precision and more recent studies with larger datasets have shown indications that a causal 
protective effect of HDL-C may exist, although this analysis is complicated by pleiotropic effects 
of the genetic variants used as instrumental variables.  
 
In light of these outstanding questions, which limit the design of anti-atherogenic therapies 
directed at LXR or HDL, we propose the following aims: (1) to define the mechanistic basis of 
LXR’s anti-inflammatory and anti-atherogenic effects, and (2) to use rigorous, powerful, and 
pleiotropy-adjusted statistical approaches to test whether genetic variants in HDL-C are linked to 
cardiovascular event risk. In the present work, we establish that LXR mediates inflammatory gene 
repression via a direct, cis-repressive function and that genetic variants conferring increases in 
HDL-C are associated with protection from CAD events. These studies will support the ongoing 
development of selective agonists for LXR that dissociate the beneficial anti-atherogenic function 
of LXR from its lipogenic activity and agents that increase the function of HDL in reverse 
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The activation of liver X receptor (LXR) promotes cholesterol efflux and repression of 
inflammatory genes with anti-atherogenic consequences. The mechanisms underlying the 
repressive activity of LXR are controversial and have been attributed to cholesterol efflux or to 
transrepression of activator protein-1 (AP-1) activity. Here, we find that cholesterol efflux 
contributes to LXR repression, while direct repressive functions of LXR also play a key role but 
are independent of AP-1. We use assay for transposase-accessible chromatin using sequencing 
(ATAC-seq) to show that LXR reduces chromatin accessibility in cis at inflammatory gene 
enhancers containing LXR binding sites. Targets of this repressive activity are associated with 
leukocyte adhesion and neutrophil migration. Consequently, LXR agonist treatment suppresses 
neutrophil recruitment in a mouse model of sterile peritonitis and represses integrin gene 
expression in atherosclerotic lesion myeloid cells. These studies suggest a model of repression 
in which liganded LXR binds in cis to canonical nuclear receptor binding sites and represses pro-




Macrophage inflammatory and metabolic processes determine the progression of several 
inflammatory diseases, such as atherosclerosis (Murray and Wynn, 2011). During atherogenesis, 
macrophages in the artery wall become cholesterol-loaded and produce inflammatory cytokines, 
leading to leukocyte recruitment and plaque destabilization (Moore and Tabas, 2011). The liver X 
receptor (LXR) is a nuclear receptor with two isoforms, LXRα and LXRβ, that respond to 
oxysterols generated during cellular cholesterol loading by promoting cholesterol efflux and 
inflammatory gene repression (Schulman, 2017). LXR agonists are potently anti-inflammatory 




Systemic LXR activation leads to induction of hepatic lipogenesis, prompting a search for specific 
anti-atherogenic functions of LXR that can be dissociated from hepatotoxic effects of LXR 
activators (Schulman, 2017). Thus, it has been reported that LXR protects from atherogenesis 
both through induction of cholesterol efflux transporters and through transrepression of 
macrophage inflammatory genes (Kappus et al., 2014). LXR’s repressive activity has been 
attributed to the formation of a complex containing Small Ubiquitin-like Modifier (SUMO)-modified 
LXR and the corepressor Nuclear CoRepressor (NCoR) with affinity for the inflammatory 
transcription factor activator protein-1 (AP-1) (Ghisletti et al., 2009; Ghisletti et al., 2007). 
Alternatively, it has been reported that LXR SUMOylation and NCoR may be dispensable for gene 
repression by LXR, and certain anti-inflammatory activities of LXR may reflect the metabolic 
functions of LXR targets, including the cholesterol efflux transporter ATP-Binding Cassette 
Transporter A1 (ABCA1) (Ito et al., 2015).  
 
Here, we use genetic and pharmacological models to establish that LXR repression is only partly 
dependent on cholesterol efflux and independent of AP-1 transactivation. Rather, based on 
studies using RNA sequencing (RNA-seq), assay for transposase-accessible chromatin using 
sequencing (ATAC-seq), and alignment of LXR chromatin immunoprecipitation-sequencing 
(ChIP-seq) with ATAC-seq data, the direct repressive function of LXR appears to be mediated 
through cis-binding of LXR to enhancer elements, leading to chromatin closure. LXR repression 
specifically regulates a subset of genes comprising chemokines and adhesion molecules involved 
in regulating neutrophil migration in the setting of low-grade inflammation. We demonstrate that 
LXR agonist treatment attenuates neutrophil migration during sterile inflammation in vivo, which 
is associated with LXR cis-repression and regulation of cholesterol metabolism in a cell-intrinsic 
manner. Furthermore, LXR agonist treatment leads to repression of integrin gene expression in 
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atherosclerotic lesional macrophages. Thus, LXR regulates inflammation and neutrophil migration 
through both metabolic and repressive functions.  
 
Results 
Cholesterol efflux transporters partly mediate LXR repression  
To study mechanisms of inflammatory gene repression by LXR, we used bone marrow-derived 
macrophages (BMDM) treated with the inflammatory Toll-like Receptor 4 (TLR4) agonist 
lipopolysaccharide (LPS) and the LXR agonist T0901317 (T0) and genetically or 
pharmacologically perturbed potential mediators of LXR functions. LXR activation by T0 for 3 
hours prior to LPS stimulation is associated with repression of the inflammatory genes Cox2 and 
Il1b (Figure 2.2A). This repressive effect of T0 is lost at high doses of LPS (Figure 2.2B). T0 
activates LXR as well as FXR and PXR in hepatocytes and ROR-γt in T cells (Houck et al., 2004; 
Mitro et al., 2007; Solt et al., 2012). However, the anti-inflammatory activity of T0 in macrophages 
is abrogated by LXRα/β knockout in macrophages, demonstrating specificity for LXR (Figure 
S1A).  
 
We used this model to examine the requirement for LXR targets in inflammatory gene repression 
by LXR. The LXR target ABCA1 has been reported to antagonize TLR4 signaling by interfering 
with its adaptor protein MYD88 (Ito et al., 2015). Consistent with earlier studies, we found that 
knockout of Abca1 and the related cholesterol efflux transporter Abcg1 in macrophages partly but 
significantly attenuates the anti-inflammatory effect of LXR agonists (Figure 2.1A, B). We used 
Myd88 knockout macrophages to assess the requirement for this potential target of cholesterol 
depletion in the repressive effect of T0. Knockout of Myd88 is associated with reduced expression 
of Cox2 and Il1b (Figure 2.1C), which may alter mechanisms of inflammatory gene induction. With 
this caveat, we observed repression of Cox2 and Il1b by T0 in these macrophages, suggesting a 
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MYD88-independent effect (Figure 2.1C). In sum, cholesterol efflux transporters induced by LXR 
appear to play a role in LXR repression in addition to other activities of LXR or LXR targets.  
 
Other LXR targets involved in metabolism, such as lysophosphatidylcholine acyltransferase 3 
(Lpcat3), stearoyl-CoA desaturase 2 (Scd2), and the efferocytosis receptor Mertk, have also been 
linked to anti-inflammatory effects in various models (A-Gonzalez et al., 2009; Li et al., 2013; 
Rong et al., 2013). We addressed whether they play a role in LXR repression in macrophages 
using loss-of-function approaches. Knockout of Lpcat3 in macrophages reduces 
phosphatidylcholine polyunsaturated fatty acid (PUFA) content (Figure 2.2C) but has no effect on 
LXR repression of Cox2 and Il1b (Figure 2.1D). Likewise, knockdown of Scd2 by siRNA does not 
affect LXR repression (Figure 2.1E; Figure 2.2D). MERTK blockade using a neutralizing antibody 
approach (Sen et al., 2007) similarly has no effect on repressive effects of the LXR agonist T0 in 
macrophages (Figure 2.2E).  
 
These findings suggest a potential role for LXR in direct repression of inflammatory gene 
enhancers, as reported in earlier studies in which LXR was proposed to interfere with AP-1 
transactivation (Ghisletti et al., 2009). Thus, we inhibited LPS-inducible AP-1 activation using 
inhibitors of mitogen-activated protein kinases (MAPKs) (Tong et al., 2016), which phosphorylate 
and activate AP-1 (Kawai and Akira, 2010). MAPK inhibitor treatment markedly reduces Cox2 
and Il1b expression, consistent with defective AP-1 activation (Figure 2.1F). With the caveat that 
gene expression is markedly reduced in this setting, Cox2 and Il1b remain LPS-inducible and 
repressed by T0 (Figure 2.1F). Together these observations suggest that direct repression by 
LXR may be independent of MAPK/AP-1 signaling, which is inconsistent with existing mechanistic 





Figure 2.1 Cholesterol efflux transporters partly mediate LXR repression  
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Figure 2.1. Cholesterol efflux transporters partly mediate LXR repression 
(A) Abca1fl/flAbcg1fl/fl (floxed ctrl) or LysMCre Abca1fl/flAbcg1fl/fl (Mac-ABCDKO) BMDM were treated 
for 3 hours with 500 nM T0 before stimulation with 10 ng/mL LPS for 2 hours.  
(B) Data in (A) plotted as % repression normalized to the extent of LPS-inducible gene expression 
in each genotype.  
(C) WT or Myd88-/- BMDM were treated as in (A).  
(D) Lpcat3fl/fl (floxed ctrl) or LysMCre Lpcat3fl/fl (Mac-Lpcat3KO) BMDM were treated as in (A).  
(E): BMDM were transfected with siSCD2 Smartpool siRNA or non-targeting siRNA (siCtrl) for 24 
hours, rested for 24 hours, and then treated as in (A).  
(F) BMDM were treated with MAPK inhibitors (10 μM PD0325901 and 1 μM BIRB0796) and then 
treated as in (A).  
mRNA expression was evaluated by qPCR and mean +/- SEM is plotted. n = 4 biological 
replicates. Significance was determined by one-way ANOVA with Tukey’s post-hoc test (A, C-F) 
or Student’s t-test with Benjamini-Hochberg multiple testing correction (B). (*) P < 0.05, (**) P < 
0.01, (***) P < 0.001 for T0 treatment vs control; (#) P < 0.05, (##) P < 0.01, (###) P < 0.001 for 
alternative genotype; (†) P < 0.05, (††) P < 0.01, (†††) P < 0.001 for LPS vs Veh. Data is 









Figure 2.2 Specificity and validation of in vitro models of LXR repression  
(A) WT or Nr1h3-/- Nr1h2-/- (LXRαβ-/-) BMDM were treated for 3 hours with 500 nM T0 before 
stimulation with 10 ng/mL LPS for 2 hours.  
(B) WT BMDM were treated for 3 hours with 500 nM T0 before stimulation with 0, 10, 50, or 100 
ng/mL LPS as indicated.  
(C) Phosphatidylcholine (PC) species of WT and LysMCre Lpcat3fl/fl (Mac-Lpcat3KO) BMDM were 
measured by infusion-based high-resolution mass spectroscopy. Relative levels of PUFA-
containing PC are shown.  
(D) BMDM were treated for 24 hours with an siRNA Smartpool targeted against SCD2 (siSCD2) 
or with a nontargeting control Smartpool (siCtrl) and then rested for 24 hours. Scd2 mRNA 
expression was determined at the time of experiment 48 hours after transfection.  
(E) BMDM were pretreated with MERTK neutralizing antibody (nMERTK) or control goat IgG for 
3 hours at a concentration of 20 µg/mL and then treated as in (A).  
mRNA expression was evaluated by qPCR. Mean +/- SEM is plotted. n = 4 biological replicates 
(A-B, D-E) or 5-6 biological replicates (C). Significance was determined by one-way ANOVA with 
Tukey’s post-hoc test (A, E), two-way ANOVA with Sidak’s post-hoc test (B), or Student’s t-test 
with Benjamini-Hochberg multiple testing correction (C, D). (*) P < 0.05, (**) P < 0.01, (***) P < 







LXR agonist closes chromatin at inflammatory gene enhancers  
To further explore potential mechanisms responsible for LXR repression of inflammatory genes, 
we assessed the identity of gene regulatory elements associated with inflammatory gene 
repression using Assay for Transposase Accessible Chromatin (ATAC)-seq. ATAC-seq identifies 
genomic regions susceptible to DNA insertion by Tn5 transposase, and these regions are 
associated with gene-regulatory activity (Buenrostro et al., 2013). Using ATAC-seq, we 
determined open chromatin regions in control macrophages or macrophages treated with T0, 
LPS, or both (Table 2.1). We focused our analysis on macrophage enhancers, defined by 
activating histone marks H3K27ac or H3K4me2 in published primary macrophage ChIP-seq data 
(Oishi et al., 2017). Enhancer filtering captured 70% of open chromatin regions and limited our 
analysis to regions likely to be involved in macrophage gene expression (Lavin et al., 2014). 
Principal components analysis of ATAC signal over all macrophage enhancers showed that 
replicates cluster by condition, establishing the reproducibility of the assay, with a strong effect of 
LPS and a moderate effect of T0 in the first two principal components (Figure 2.4A). 
 
T0 treatment leads to decreases in chromatin accessibility at targets of LXR repression, such as 
Il1b (Figure 2.3A), and moderate increases in chromatin accessibility at LXR targets, such as 
Srebf1 (Figure 2.3B). On a genome-wide basis, T0 treatment is associated with closure of 6474 
enhancers (“T0-closed”) and opening of 224 enhancers (“T0-opened”) (Figure 2.4B). We used 
Gene Ontology (GO) analysis to assess cellular functions that may be regulated by each 
enhancer set by determining the gene nearest to each enhancer and performing GO analysis 
(Thomas et al., 2003) on the corresponding gene set. T0-closed enhancers are nearest to genes 
associated with GO categories related to TLR signaling, positive regulation of T cell activation, 
and regulation of phagocytosis, linking the observed chromatin closure events to LXR’s anti-
inflammatory activity (Figure 2.3C). Sequence motif analysis of T0-closed enhancers using 
37 
 
HOMER (Heinz et al., 2010) revealed an enrichment for nuclear receptor half-site motifs and 
direct repeat-4 (DR4) LXR response elements (Figure 2.3D), suggesting that LXR may bind 
directly at these enhancers. Analysis of enhancers closed by T0 after LPS treatment (“T0-closed-
in-LPS”), 36% of which overlap with T0-closed enhancers, confirmed the observed associations 
with inflammatory gene GO categories and nuclear receptor response element motifs (Figure 
2.4C, D).  
 
To validate our enhancer identification method, we examined the effect of LPS treatment. LPS 
treatment led to the opening of 2020 enhancers (“LPS-opened”) and closure of 4636 enhancers 
(“LPS-closed”) (Figure 2.3B). Genes nearest to LPS-opened enhancers are linked to GO 
categories related to LPS-mediated signaling and positive regulation of T cell activation, which 
are highly similar to the GO categories of genes nearest to T0-closed enhancers (Figure 2.3E). 
HOMER motif analysis of LPS-opened enhancers revealed a prominent enrichment for nuclear 
factor κB (NF-κB) and AP-1 binding sites (Figure 2.3F), consistent with previous studies of 
inflammatory enhancers (Tong et al., 2016). In untreated or TLR4-stimulated macrophages, 
ATAC signal correlates strongly with H3K27 acetylation signal measured in published primary 
macrophage ChIP-seq data (Oishi et al., 2017) (r = 0.8 for each condition, Figure 2.4E, F) and 
captures 80% of H3K27ac+ peaks, consistent with prior evidence that chromatin accessibility 
changes are linked to histone modification changes involved in transcriptional regulation (Bell et 




Table 2.1 ATAC-seq sequencing statistics  
 
 Veh T0 LPS T0+LPS 
Replicates 4 4 4 4 
Total Reads 166,571,759 142,431,581 150,110,447 142,929,398 
Reads Mapped 162,666,895 139,857,174 146,897,615 139,872,799 
Unique Reads Mapped 68,804,852 67,716,584 64,099,577 59,297,287 
Fr. Reads in Peak (FRiP) 0.143 0.094 0.122 0.109 
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Figure 2.3 LXR agonist closes chromatin at inflammatory gene enhancers.  
WT BMDM were treated for 3 hours with 500 nM T0 before stimulation with 10 ng/mL LPS for 2 
hours and harvested for ATAC-seq. Accessible regions were determined from ATAC-seq data 
and analysis was restricted to macrophage H3K4me2- or H3K27ac-marked enhancers defined 
by Oishi et al., 2017.  
(A-B) Representative genome browser track of chromatin accessibility signal around the T0-
repressed gene Il1b (A) and T0-induced gene Srebf1  
(B) with vehicle or T0 treatment. Signal is plotted in units of reads per genomic content (RPGC).  
(C) PANTHER GO categories enriched in genes nearest to T0-closed enhancers (Bonferroni-
adjusted P < 0.05).  
(D) HOMER de novo motifs enriched in T0-closed enhancers (P < 1 x 10-12; top 5 motifs 
displayed). NR-half: nuclear receptor half-site. LXRE: LXR response element. FE: fold 
enrichment.  
(E) PANTHER GO categories enriched in genes nearest to LPS-opened enhancers (Bonferroni-
adjusted P < 0.05).  
(F) HOMER de novo motifs enriched in LPS-opened enhancers (P < 1 x 10-12; top 5 motifs 
displayed).  













Figure 2.4 Characterization of T0-related chromatin changes by ATAC-seq  
(A) PCA analysis of ATAC signal over all macrophage enhancers by replicate.  
(B) Number of enhancers opened or closed by T0 and LPS treatments.  
(C) PANTHER GO categories enriched in genes nearest to T0-closed-in-LPS enhancers 
(Bonferroni-adjusted P < 0.05).  
(D) HOMER de novo motifs enriched in T0-closed-in-LPS enhancers (P < 1 x 10-12; top 5 motifs 
displayed). FE: fold enrichment.  
(E-F) Correlation of ATAC signal with H3K27ac signal from Oishi et al., 2017 over macrophage 
enhancers from untreated macrophages (E) or TLR4-stimulated (TLR4-stim.) macrophages (F).  




LXR binding by ChIP-seq localizes at T0-closed enhancers 
Motif analysis of T0-closed enhancers suggested that LXR may bind directly at these sites. To 
further assess this possibility, we aligned LXR ChIP signal from a published dataset (Oishi et al., 
2017) to enhancers closed or opened by T0 from our ATAC-seq data. In this published LXR ChIP-
seq dataset, the LXR agonist GW3965 was used to activate LXR; specificity for LXR binding was 
established at the level of antibody recognition of LXR and confirmed by motif enrichment (Oishi 
et al., 2017). LXR ChIP peaks are closely aligned with regions where T0 treatment reduced 
chromatin accessibility, as at Il1b (Figure 2.5A). On a genome-wide basis, LXR ChIP signal is 
superimposed on T0-closed enhancers, producing a single peak of LXR ChIP signal in histograms 
centered on closed enhancers (Figure 2.5B). Plotting the individual LXR ChIP signals for each 
enhancer after aligning the enhancer centers showed that LXR binding is present at many 
enhancers before LXR activation or TLR4 stimulation by the agonist Kdo2-Lipid A (KLA) and at 
most enhancers after LXR or TLR4 stimulation (Figure 2.5C).  
 
Alignment of LXR ChIP-seq to T0-closed-in-LPS enhancers revealed that LXR ChIP signal 
localized to these regions as well (Figure 2.6A, B). LXR ChIP signal intensity is similar between 
T0-closed and T0-closed-in-LPS enhancers, suggesting a common mechanism of LXR 
recruitment in the presence or absence of inflammatory stimulation. At T0-opened enhancers, the 
LXR ChIP signal is similarly enriched (Figure 2.6C, D), consistent with the established cis-
activating activity of LXR at enhancers of LXR targets. GW3965 treatment increased LXR ChIP 
signal at enhancers closed by T0 (Figure 2.5B), consistent with previous observations that DNA-
binding affinity of LXR is increased with LXR agonist treatment (Pehkonen et al., 2012). In 
combination with the enrichment for LXR binding sites in T0-closed enhancers, the alignment of 





Figure 2.5 LXR binding by ChIP-seq localizes at T0-closed enhancers  
45 
 
Figure 2.5 LXR binding by ChIP-seq localizes at T0-closed enhancers  
LXR ChIP-seq signal from Oishi et al., 2017 was plotted at enhancer sets derived from ATAC-seq 
of BMDM treated for 3 hours with 500 nM T0 before stimulation with 10 ng/mL LPS for 2 hours.  
(A) Representative genome browser track of LXR ChIP signal around the T0-repressed gene Il1b. 
Signal is plotted in units of reads per genomic content (RPGC). 
 (B) Histogram of LXR ChIP-seq signal centered on T0-closed enhancers. LXR-notr: chromatin 
from resting thioglycolate-elicited macrophages (TGEM) immunoprecipitated with anti-LXR 
antibody (notr: no treatment); LXR-KLA1h: chromatin from TGEM stimulated with TLR4 agonist 
KLA for 1 hour; LXR-GW: chromatin from TGEM treated with LXR agonist GW3965 for 24 hours.  
(C) Heatmap of LXR ChIP-seq signal as in (B) centered on T0-closed enhancers.  









Figure 2.6 LXR ChIP signal is present at T0-closed-in-LPS and T0-opened enhancers  
(A) Histogram of LXR ChIP-seq signal from Oishi et al., 2017 centered on T0-closed-in-LPS 
enhancers. LXR-notr: chromatin from resting thioglycolate-elicited macrophages (TGEM) 
immunoprecipitated with anti-LXR antibody (notr: no treatment); LXR-KLA1h: chromatin from 
TGEM stimulated with TLR4 agonist KLA for 1 hour; LXR-GW: chromatin from TGEM treated with 
LXR agonist GW3965 for 24 hours.  
(B) Heatmap of LXR ChIP-seq signal as in (A) centered on T0-closed-in-LPS enhancers.  
(C) Histogram of LXR ChIP-seq signal as in (A) centered on T0-opened enhancers.  
(D) Heatmap of LXR ChIP-seq signal as in (A) centered on T0-opened enhancers.  









Chromatin accessibility changes with T0 are linked to gene expression changes 
We used RNA-seq to determine the functional correlates of T0-associated changes in chromatin 
accessibility at the level of gene expression. We treated BMDM with or without T0 for 3 hours 
before stimulation with 10 ng/mL LPS for 2 hours, identical to the conditions in which we 
established that Cox2 and Il1b repression by T0 is LXR-dependent. Comparison of genes and 
enhancers regulated by T0 revealed that 56% of >1.5-fold T0-induced genes are associated with 
a T0-opened or T0-opened-in-LPS enhancer within 100 kb of the transcription start site (Figure 
2.7A), while 78% of >1.5-fold T0-repressed genes are associated with a T0-closed or T0-closed-
in-LPS enhancer (Figure 2.7B). These associations are significant compared with randomly 
selected genes when the enhancer-promoter distance distributions are systematically compared 
(Figure 2.7C, D), as expected based on the association of chromatin accessibility with gene 
regulatory activity. Unexpectedly, 81% of T0-induced genes are also associated with either T0-
closed or T0-closed-in-LPS enhancers (Figure 2.7B), suggesting that cis-binding of LXRs near 
these genes leads to both chromatin opening and closure events. Thus, the proximity of 
enhancers regulated by T0 to T0-induced or T0-repressed genes provides evidence that the 
observed accessibility changes correlate with transcriptional regulation events and supports our 
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Figure 2.7 Chromatin accessibility changes with T0 are linked to gene expression changes 
Transcription start site (TSS) positions of differentially expressed genes in RNA-seq of BMDM 
treated with T0 for 3 hours and 10 ng/mL LPS for 2 hours were compared to positions of 
enhancers opened or closed by T0 in ATAC-seq data collected from BMDM in the same 
conditions.  
(A-B) Percentage of genes in T0-induced, T0-repressed, or random genes with an enhancer 
opened by T0 (A) or closed by T0 (B) in the control or LPS-stimulated condition within 100kb of 
the TSS.  
(C-D) Distribution of distances from TSS to nearest enhancer for T0-induced, T0-repressed, or 
random genes to enhancers opened by T0 (C) or closed by T0 (D) in the control or LPS-stimulated 
condition.  
n = 4 biological replicates (ATAC-seq) or 3 biological replicates (RNA-seq). Significance was 
determined by Kruskal-Wallis nonparametric one-way ANOVA with Dunn post-hoc test. (*) P < 





LXR represses neutrophil migration genes 
In total, T0 treatment represses 242 genes and induces 170 genes at a False Discovery Rate 
(FDR) threshold of 5% (Figure 2.8A). More than half of T0-repressed genes (61%) are LPS-
inducible inflammatory genes (Figure 2.8A). GO analysis showed that T0-repressed genes are 
associated with immune-related functions, including regulation of T-helper cell differentiation, 
leukocyte cell-cell adhesion, chemokine signaling, and granulocyte chemotaxis (Figure 2.8B). T0-
induced genes are associated with lipoprotein activity and cellular lipid metabolism (Figure 2.8C). 
As the roles of LXR in lipid metabolism and control of T cell priming are well-established (Ito et 
al., 2016), we investigated the enrichment of multiple GO categories regulating leukocyte and 
specifically neutrophil migration among T0-repressed genes. Leukocyte cell-cell adhesion and 
granulocyte chemotaxis genes repressed by T0 include the cytokine Il1b, chemokines, and 
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Figure 2.8 LXR represses neutrophil migration genes 
WT BMDM were treated for 3 hours with 500 nM T0 before stimulation with 10 ng/mL LPS for 2 
hours and harvested for RNA-seq.  
(A) Heatmap of all induced or repressed genes at 5% FDR, colored by row-normalized z-score, 
with extent of induction by LPS indicated on right.  
(B) PANTHER GO categories enriched in T0-repressed genes (Bonferroni-adjusted P < 0.05).  
(C) PANTHER GO categories enriched in T0-induced genes (Bonferroni-adjusted P < 0.05).  
(D-E) Row-normalized z-score for T0-repressed genes in the GO category “Leukocyte cell-cell 
adhesion” (D) or “Granulocyte chemotaxis” (E).  




LXR activation suppresses neutrophil migration in vivo 
The repression of genes associated with leukocyte cell-cell adhesion and granulocyte chemotaxis 
in inflammatory macrophages led us to consider whether LXR activation would block neutrophil 
recruitment during sterile inflammation. We used the yeast cell wall component zymosan A to 
elicit sterile peritonitis, which is characterized by infiltration of neutrophils in the onset phase 4-24 
hours post zymosan injection, followed by resolution over approximately 3 days (Newson et al., 
2014). Mice were treated for 3 days with 10 mg/kg T0 by daily oral gavage and given a final dose 
2 hours before intraperitoneal injection of 0.1 mg zymosan (Figure 2.9A). Peritoneal exudates 
were collected 0, 12, and 24 hours after zymosan injection, and peritoneal exudate cells were 
identified as neutrophils (Ly6G+) or macrophages (F4/80+) by flow cytometry.  
 
LXR agonist treatment leads to an overall decrease in peritoneal exudate cell counts (P < 0.05 by 
two-way ANOVA; Figure 2.9B). This effect is largely driven by a 44% decrease in neutrophil 
recruitment during inflammation onset (Figure 2.9C). Recruitment of monocyte-derived 
macrophages starts between 12-24 hours post zymosan injection, at which point resident 
macrophages are no longer recovered (Bannenberg et al., 2005), and is unchanged in T0-treated 
mice compared to vehicle treated controls (Figure 2.9D). Ly6G- F4/80- peritoneal exudate cell 
counts are also unchanged (Figure 2.10A). Blood neutrophil counts are unchanged after 3 days 
of T0 treatment, suggesting that the effect of T0 on exudate neutrophil counts is a consequence 
of defective neutrophil recruitment (Figure 2.10B). Exudate protein content reflects leakage of 
plasma proteins into the peritoneum (Bannenberg et al., 2005) and is unchanged after T0 





The specific defect in neutrophil migration suggests a potential role for LXR in regulating genes 
involved in lipid metabolism or cell adhesion in these cells. Thus, we assayed mRNA from 
neutrophil-rich early peritoneal exudates (4 hours after zymosan administration) and found that 
LXR targets Abca1 and Abcg1 are induced, while the adhesion molecule Itgb2 is repressed 
(Figure 2.9E). Interestingly, we found that Abca1 and Abcg1 are highly expressed and induced 
by T0 in isolated Ly6G+ exudate neutrophils (Figure 2.9F), suggesting that T0 has a cell-intrinsic 
effect on neutrophil cholesterol metabolism. Expression of Cox2 and Il1b, on the other hand, is 
unchanged in peritoneal exudate mRNA, potentially due to the high level of inflammatory gene 
expression elicited by zymosan exposure, which exceeds the level of induction of these genes at 
which they are sensitive to LXR repression in vitro, similar to the effects of high levels of LPS 
(Figure 2.10D, E). These results suggest that LXR may suppress neutrophil migration through 
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Figure 2.9 LXR activation suppresses neutrophil migration in vivo 
Mice were treated with T0 or vehicle before induction of zymosan peritonitis.  
(A) Dosing schedule for treatments and harvest of peritoneal exudates  
(B-D) Total peritoneal exudate cell (B), neutrophil (C), and macrophage (D) counts at 0, 12, or 24 
hours after zymosan injection. Cell counts were determined by flow cytometry.  
(E) Peritoneal exudate cell mRNA expression at 4 hours after zymosan injection was measured 
by qPCR.  
(F) Peritoneal exudate leukocyte subsets were isolated using anti-Ly6G- or anti-F4/80-conjugated 
magnetic beads at 4 hours after zymosan injection and mRNA expression was measured by 
qPCR.  
Mean +/- SEM is plotted. n = 4-5 biological replicates. Significance was determined by two-way 
ANOVA with Sidak’s post-hoc test (B-D) or by Student’s t-test with Benjamini-Hochberg multiple 
testing correction (E-F). (*) P < 0.05, (**) P < 0.01, (***) P < 0.001 for individual timepoint. (†) P < 
0.05, (††) P < 0.01, (†††) P < 0.001 for treatment effect by 2-way ANOVA. (#) P < 0.05, (##) P < 






























Figure 2.10 Effect of T0 on parameters related to zymosan peritonitis severity 
(A) Ly6G- F4/80- cell counts at 0, 12, or 24 hours after zymosan injection were determined by 
flow cytometry.  
(B) Circulating neutrophil counts with or without T0 treatment were determined by flow cytometry.  
(C) Level of exudate protein determined by BCA assay at 2h after zymosan injection.  
(D) Inflammatory gene expression in resident peritoneal macrophages with or without T0 
treatment.  
(E) Inflammatory gene expression in inflammatory peritoneal macrophages 2h after zymosan 
injection.  
Arrows indicate magnitude of induction of each gene by 10 ng/mL LPS in vitro. n = 4-6 biological 
replicates (A-C, E) or 3 biological replicates (D). Significance was determined by two-way ANOVA 
with Sidak’s post-hoc test (A) or by Student’s t-test with Benjamini-Hochberg multiple testing 




LXR represses integrin gene expression in atherosclerosis 
We assessed whether LXR activation leads to cholesterol efflux transporter induction and 
repression of inflammatory genes in aortic myeloid cells from hypercholesterolemic mice. We fed 
9 week-old Apoe-/- mice Western-type diet for 3 weeks with or without T0 in the diet at a dose 
equivalent to 10 mg/kg. Myeloid cells were isolated using anti-Cd11b-conjugated magnetic beads 
from single cell preparations of isolated aortas digested with collagenase, hyaluronidase, and 
DNase I.  
 
Unexpectedly, LXR activation in aortic myeloid cells in the setting of hypercholesterolemia fails to 
induce the cholesterol efflux transporter genes Abca1 and Abcg1 (Figure 2.11A), in contrast to 
the effect of LXR agonists on macrophages and neutrophils during zymosan peritonitis (Figure 
2.9F). In lesional myeloid cells, LXR agonist treatment leads to robust increases in expression of 
other LXR targets, such as Scd2 and Mylip (Figure 2.11A). In a separate experiment, we observed 
a trend for a similar selective effect of T0 on Scd2 and Mylip expression without Abca1 or Abcg1 
induction in laser-capture microdissection-isolated atherosclerotic lesional macrophages from 16-
17 week-old Apoe-/- mice, where gene expression was measured by RNA-seq (data not shown). 
This result suggests that LXR transactivation potential may be saturated at Abca1 and Abcg1 in 
a promoter-specific manner during hypercholesterolemia. This hypothesis is consistent with the 
failure of myeloid knockout of Abca1 and Abcg1 to attenuate anti-atherogenic effects of LXR 
agonists (Kappus et al., 2014), since these agents induce cholesterol efflux transporters 
inefficiently in lesional myeloid cells.  
 
We also assessed the effect of LXR agonist treatment on expression of LXR repression targets 
in lesional myeloid cells from aortic digests by qPCR. Interestingly, LXR agonist treatment 
reduces expression of the integrin gene Itgb2, without repression of the in vitro LXR cis-repression 
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targets Cox2, Il1b, or Cxcl1 (P < 0.05 after correction for multiple comparisons; Figure 2.11B). 
The specificity of this effect closely matches what we observed in the setting of zymosan-induced 
peritonitis, which provides evidence that the LXR effect in this sterile inflammation model matches 
molecular features of LXR repression in the context of inflammatory disease. This result suggests 
that Itgb2 is a key target for LXR repression in myeloid cells, as it was consistently repressed by 
T0 in BMDMs, peritoneal exudate cells, and lesional myeloid cells. Thus, the anti-atherogenic 
effect of LXR agonists may be mediated in part through cis-repression effects at adhesion 
molecules such as Itgb2. ITGB2/CD18 is an integrin subunit of the leukocyte adhesion molecules 
lymphocyte function-associated antigen 1 (LFA-1) and macrophage-1 antigen (Mac-1), which 
bind to endothelial vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion 
molecule-1 (ICAM-1) during leukocyte extravasation (Dunne et al., 2002). Thus, suppression of 
Itgb2 by LXR may inhibit inflammatory cell recruitment into atherosclerotic lesions, which will be 
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Figure 2.11 LXR represses integrin gene expression in atherosclerosis 
Lesional myeloid cells were isolated from aortic digests of hypercholesterolemic Apoe-/- mice on 
Western-type diet with or without T0 and cells were lysed for RNA.  
(A) Effect of T0 treatment on LXR target expression.  
(B) Effect of T0 treatment on LXR repression target expression.  
Mean +/- SEM and individual points are plotted. n = 10 biological replicates. Significance was 
determined by Student’s t-test with Benjamini-Hochberg multiple testing correction. (*) P < 0.05, 





LXR agonists suppress inflammation, which has stimulated widespread interest in their 
development as therapeutics for diseases such as dermatitis, rheumatoid arthritis, and 
atherosclerosis (Joseph et al., 2003; Kappus et al., 2014; Li et al., 2010). This activity has been 
linked to either LXR transrepression or cholesterol efflux, but recent studies have challenged the 
role of transrepression by LXR in control of inflammation (Ito et al., 2015). We confirmed a role 
for cholesterol efflux in LXR repression, but uncovered a cis-repressive activity of LXR acting at 
inflammatory gene enhancers that plays a major role in LXR repression. We further established 
that this activity targets genes associated with several pro-atherogenic leukocyte functions, 
including neutrophil migration, and found that LXR agonist treatment blocks neutrophil recruitment 
during sterile inflammation and represses integrin gene expression in atherosclerosis. 
 
The direct repressive effect of LXR agonists has been attributed to an NCoR-dependent 
repressive function of SUMOylated LXR acting generally at the stimulus-dependent transcription 
factor AP-1 (Ghisletti et al., 2009). This model suggests that during LXR repression, LXR binds 
indirectly to corepressor complexes around AP-1 response elements without a defined role for 
the DNA-binding domain of LXR. In contrast, we find that the direct repressive activity of LXR is 
associated with binding in cis to LXR response elements and does not appear to require AP-1 
activity, indicating that LXR repression is targeted by genome-encoded regulatory interactions to 
certain inflammatory genes where LXR binds directly. This proposed mechanism of repression is 
similar to the cis-repressive activity of the glucocorticoid receptor (Uhlenhaut et al., 2013). By 
comparison, cholesterol efflux-dependent anti-inflammatory functions of LXR, which interfere with 
TLR signaling, have been shown to broadly interfere with TLR signaling and inflammatory gene 




The combined activities of LXR repression attenuate the expression of neutrophil cell adhesion 
and migration genes, and we observed that LXR activation limits neutrophil recruitment during 
sterile peritonitis. Our data suggest that the cis-repressive function of LXR, by suppressing 
integrin gene expression, may play a role in this activity. In addition, we found that neutrophil 
expression of cholesterol efflux transporters is robust and strongly stimulated by T0. A role for 
cholesterol efflux in limiting inflammatory migration of these cells is consistent with previous 
reports that ABCA1 activity is associated with decreased migration in macrophages (Zhu et al., 
2012). Thus, it is likely that both cis-repression and cholesterol efflux contribute to the efficacy of 
T0 in suppression of neutrophilic inflammation.  
 
In atherosclerosis, LXR agonists are protective even in the absence of cholesterol efflux 
transporters, highlighting the importance of the dual functions of LXR in metabolism and 
inflammatory gene control (Kappus et al., 2014). The repression of neutrophil migration genes by 
LXR agonists may be particularly important in this context, as mice with cholesterol efflux 
transporter deficiency in myeloid cells have prominent neutrophil accumulation and neutrophil 
extracellular trap formation in lesions (Westerterp et al., 2018), and we show that LXR cis-
repression of the integrin gene Itgb2 occurs in lesional myeloid cells. Although LXR agonists have 
hepatotoxic effects, targeting metabolic and inflammatory functions of neutrophils or 
macrophages by activating LXR in these cells specifically remains a promising therapeutic 





Table 2.2 Key Resources Table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
F4/80-Pacific Blue Thermo Cat# MF48028; 
RRID:AB_10373419 
Ly6G-FITC  BioLegend Cat# 127605; 
RRID:AB_1236488 
Mer neutralizing antibody R&D Systems Cat# AF591; 
RRID:AB_2098565 
Normal goat IgG control R&D Systems Cat# AB-108-C; 
RRID:AB_354267 
Chemicals, Peptides, and Recombinant Proteins 
T0901317 Selleckchem Cat# S7076 
Lipopolysaccharide Cell Signaling Cat# 14011 
Lipofectamine RNAiMAX Thermo Cat# 13778075 
Scd2 SMARTpool siRNA Dharmacon/GE Cat# L-045507-01-
0005 
Non-targeting control SMARTpool siRNA Dharmacon/GE Cat# D-001810-10-
05 
PD0325901 Sigma Cat# PZ0162 
BIRB0796 AXON Medchem Cat# 1358 
Critical Commercial Assays 
Nextera DNA library prep kit Illumina Cat# FC-121-1030 
NEBNext RNA Ultra library prep kit NEB Cat# E7530S 
F4/80 microbeads, ultrapure, mouse Miltenyi Cat# 130-110-443 
Ly6G microbeads, mouse Miltenyi Cat# 130-092-332 
BCA protein assay kit Pierce Cat# 23225 
Deposited Data 
LXR agonist ATAC-seq This paper GEO: GSE109998 
LXR agonist RNA-seq This paper GEO: GSE109997 
LXR ChIP-seq Oishi et al., 2017 GEO: GSE79423 
H3K27ac ChIP-seq Oishi et al., 2017 GEO: GSE79423 
H3K4me2 ChIP-seq Oishi et al., 2017 GEO: GSE79423 
Experimental Models: Organisms/Strains 
mouse: Nr1h3-/- Nr1h2-/-;  
B6.129S1.129X1-Nr1h2tm1.1Gstr Nr1h2tm1.1Gstr 
Alberti et al., 2001 MGI Cat# 2653351, 
RRID:MGI:2653351 




JAX Cat# 009088; 
RRID:MGI:4430210 
mouse: Abca1fl/flAbcg1fl/fl;  
B6.Cg-Abca1tm1Jp Abcg1tm1Tall/J 
Westerterp et al., 2013 JAX Cat# 021067; 
RRID:IMSR_JAX:02
1067 
Mouse: Lpcat3fl/fl;  
B6.Cg-Lpcat3tm1.1Igl/N 





















Mouse Cox2 forward primer:  
AACCGCATTGCCTCTGAAT 
Nasser et al., 2013 N/A 
Mouse Cox2 reverse primer: 
CATGTTCCAGGAGGATGGAG 
Nasser et al., 2013 N/A 
Mouse Il1b forward primer: 
GCAACTGTTCCTGAACTCAACT 
Huang et al., 2011 N/A 
Mouse Il1b reverse primer: 
ATCTTTTGGGGTCCGTCAACT 
Huang et al., 2011 N/A 
Mouse Abca1 forward primer: 
CAGCTTCCATCCTCCTTGTC 
Murphy et al., 2013 N/A 
Mouse Abca1 reverse primer: 
CCACATCCACAACTGTCTGG 
Murphy et al., 2013 N/A 
Mouse Abcg1 forward primer: 
GTACCATGACATCGCTGGTG 
Murphy et al., 2013 N/A 
Mouse Abcg1 reverse primer: 
AGCCGTAGATGGACAGGATG 
Murphy et al., 2013 N/A 
Mouse Itgb2 forward primer: 
CCCAGGAATGCACCAAGTACA 
This paper N/A 
Mouse Itgb2 reverse primer: 
CAGTGAAGTTCAGCTTCTGGCA 
This paper N/A 
Software and Algorithms 
Graphpad Prism v7.0.3 GraphPad Software https://www.graphpa
d.com/scientific-
software/prism/ 
cutadapt v1.14 Martin et al., 2011 https://cutadapt.read
thedocs.io/en/stable/
guide.html 
samtools v1.5 Li et al., 2009 http://samtools.sourc
eforge.net/ 
MACS2 v2.1.1 Zhang et al., 2008 https://github.com/ta
oliu/MACS 
Deeptools v2.5.4 Ramirez et al., 2014 https://deeptools.rea
dthedocs.io/en/devel
op/ 









PANTHER GO  Thomas et al., 2003 http://www.geneontol
ogy.org/page/go-
enrichment-analysis 
HOMER v4.9.1 Heinz et al., 2010 http://homer.ucsd.ed
u/homer/ 
HISAT2 v2.1.0 Kim et al., 2015 https://ccb.jhu.edu/s
oftware/hisat2/index.
shtml 
featureCounts v1.5.0r Liao et al., 2014 http://subread.sourc
eforge.net/ 

























Materials and Methods 
Experimental Model and Subject Details 
Animals 
Wildtype C57BL/6J mice were obtained from The Jackson Laboratory (stock #000664). LXR KO 
(Nr1h3-/- Nr1h2-/-) mice were generated as described previously (Alberti et al., 2001) and were 
backcrossed into the C57BL/6J background for at least 10 generations. Myd88-/- mice were 
obtained from The Jackson Laboratory (stock #009088) and were backcrossed into the C57BL/6J 
background for at least 10 generations. LysMCre Abca1fl/flAbcg1fl/fl and littermate control 
Abca1fl/flAbcg1fl/fl mice were generated as described previously (Westerterp et al., 2013). Lpcat3fl/fl 
were generated as described previously (Kabir et al., 2016) and crossed with LysMCre mice from 
The Jackson Laboratory (stock #004781) to generate mice with myeloid Lpcat3 deficiency and 
littermate controls. Apoe-/- mice were obtained from The Jackson Laboratory (stock #002052) and 
were backcrossed into the C57BL/6J background for at least 10 generations. 
 
All mice were housed at Columbia University Medical Center according to animal welfare 
guidelines. Animals were kept under specific pathogen-free conditions with ad libitum access to 
both food and water. Mice were fed irradiated chow diet (Purina Mills diet 5053) or Western-type 
diet (Envigo TD.88137). Housing temperatures were kept within a range of 71-73°F (21.7-22.8°C). 
Water and cages were autoclaved and cages were changed once weekly. The health status of 
the mice was monitored using a dirty bedding sentinel program and no health status issues or 
changes in immune status were identified. Mice were not used for any procedures prior to bone 
marrow isolation or peritonitis experiments. Female mice aged 8-12 weeks (weight 18-25 g) were 
used for all experiments. For in vivo peritonitis experiments, age-matched mice were randomly 
assigned to treatment or control groups. No inclusion or exclusion criteria were used. All protocols 




Primary Cell Culture 
For generation of bone marrow-derived macrophages, female mice aged 8-10 weeks were 
euthanized in accordance with American Veterinary Association Panel on Euthanasia regulations 
and bone marrow was isolated from femurs and tibias. Bone marrow cells were differentiated into 
macrophages by culture in DMEM 10% FBS, 1% pen-strep supplemented with 20% L-cell 
conditioned medium in tissue culture treated plates in an incubator set at 37°C and 5% CO2. After 
7 days, macrophages were fully differentiated and subjected to a one-day serum deprivation in 
DMEM, 1% pen-strep supplemented with 4% L-cell conditioned medium to normalize exposure 
to serum-derived lipoproteins before treatment with LXR agonist and inflammatory agents as 




Female mice aged 10-12 weeks were randomly assigned to vehicle or LXR agonist treatment 
groups. Mice were pre-treated with 10 mg/kg T0901317 (Selleckchem) prepared in 0.9% 
carboxymethylcellulose solution, or vehicle alone, for 3 days by daily oral gavage. Twenty-four 
hours after the 3rd dose, mice were treated once with 10 mg/kg T0901317 prepared as above, or 
vehicle alone, by oral gavage 2 hours before intraperitoneal injection of 0.1 mg zymosan (Sigma) 
in 0.5 mL sterile PBS. At 4, 12, or 24 hours after zymosan treatment, or without zymosan injection, 
mice were euthanized in accordance with American Veterinary Association Panel on Euthanasia 
regulations. Peritoneal exudates were harvested and cells were stained with anti-F4/80 clone 
BM8 (eBioscience) and anti-Ly6G clone 1A8 (BioLegend) for analysis of cell counts by flow 
cytometry or isolated with anti-F4/80 or anti-Ly6G microbeads (Miltenyi) for RNA analysis. For 
blood neutrophil counts, blood was collected by cardiac puncture and treated with RBC lysis buffer 
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(Biolegend). Blood cells were stained with anti-CD115 clone AFS98 (Thermo) and anti-Gr1 clone 
RB6-8C5 (BD Biosciences) for analysis of cell counts by flow cytometry. Exudate protein content 
was measured by bicinchoninic acid (BCA) assay (Pierce). For peritonitis experiments, data is 
representative of two independent experiments and 4-6 mice were used for each condition, as 
indicated in the figure legends.  
 
Lesional Myeloid Cell RNA Isolation 
Apoe-/- mice at 9 weeks of age were fed Western-type diet for 3 weeks with or without T0 at a 
dose of 10 mg/kg in the diet. After this period, aortas were isolated, cleaned, and digested with 
collagenase (Liberase TM), hyaluronidase, and DNase I at 37°C for one hour as described 
(Westerterp et al., 2018). Cd11b+ cells were isolated from aortic digests using magnetic anti-
Cd11b-conjugated microbeads (Miltenyi), and RNA was isolated using RNeasy columns 
(Qiagen).  
 
BMDM Treatment and Stimulation 
For LXR agonist treatment and inflammatory stimulation of macrophages, BMDM were treated 
with LXR agonist T0901317 (Selleckchem) at a concentration of 500 nM or DMSO vehicle alone 
at a 1:10,000 dilution in serum-free medium with 4% L-cell conditioned medium for 3 hours. After 
this treatment period, macrophages were harvested directly for transposase-accessible DNA 
isolation from unstimulated cells or stimulated with 10 ng/mL LPS (Cell Signaling) added directly 
to agonist-containing medium for 2 hours before transposase-accessible DNA or RNA isolation. 
For knockdown experiments, macrophages were differentiated as described above and treated 
on day 7 with 100 nM SMARTpool siRNA (Dharmacon) against Scd2 or control non-targeting 
siRNA complexed with Lipofectamine RNAiMAX (Thermo) in OptiMEM medium (Thermo) for 24 
hours. After this period, Optimem was aspirated and replaced with DMEM, 1% pen-strep 
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supplemented with 4% L-cell supernatant for one additional day. On day 9, macrophages were 
treated with LXR agonist T0901317 at 500 nM for 3 hours and stimulated with 10 ng/mL LPS for 
2 hours. For MAPK inhibitor experiments, macrophages were treated with 10 μM PD0325901 
(Sigma) and 1 μM BIRB0796 (AXON Medchem) as described (Tong et al., 2016) starting at the 
same time as treatment with T0901317 at 500 nM for 3 hours before stimulation with 10 ng/mL 
LPS for 2 hours. For MERTK antibody neutralization experiments, anti-Mer blocking antibody 
AF591 (R&D Systems) was added 3 hours prior to treatment with T0901317 at 500 nM for 3 hours 
and stimulated with 10 ng/mL LPS for 2 hours. For each BMDM stimulation experiment, data is 
representative of two independent experiments and 3-4 independently differentiated macrophage 
cultures were used for each condition, as indicated in the figure legends. 
 
Gene Expression Analysis 
Macrophages were washed twice with cold PBS and lysed in RNA lysis buffer (Qiagen or Zymo 
Research). RNA was isolated using RNeasy kits (Qiagen) or RNA MiniPrep kits (Zymo Research). 
cDNA was prepared using first strand synthesis kits (Thermo) and qPCR was performed on an 
ABI StepOnePlus machine with SYBR reagents (Thermo). The following primers were used for 
qPCR analyses: Cox2-F: AACCGCATTGCCTCTGAAT; Cox2-R: 
CATGTTCCAGGAGGATGGAG (Nasser et al., 2012); Il1b-F: GCAACTGTTCCTGAACTCAACT; 
Il1b-R: ATCTTTTGGGGTCCGTCAACT (Huang et al., 2011); Abca1-F: 
CAGCTTCCATCCTCCTTGTC; Abca1-R: CCACATCCACAACTGTCTGG (Murphy et al., 2013); 
Abcg1-F: GTACCATGACATCGCTGGTG; Abcg1-R: AGCCGTAGATGGACAGGATG (Murphy et 
al., 2013); Itgb2-F: CCCAGGAATGCACCAAGTACA; Itgb2-R: CAGTGAAGTTCAGCTTCTGGCA 





ATAC-seq Experimental Preparation 
Samples were prepared for ATAC-seq essentially as described previously (Buenrostro et al., 
2013). Macrophages were washed twice in cold PBS, scraped in cold PBS, and counted using a 
hemocytometer. Based on this count, 50,000 cells were aliquoted and pelleted by centrifugation. 
Cell pellets were washed once with 50 µL cold PBS on ice before lysis in 50 µL hypotonic lysis 
buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 3 mM MgCl2, 0.1% IGEPAL CA-630) over the course 
of a 10 minute spin at 4°C. Pelleted nuclei were resuspended in 50 uL transposition reaction mix 
with 3 uL Nextera transposase per sample (Illumina). The reaction was stopped with 0.1% SDS 
and transposase-accessible DNA was isolated using AMPure XP beads (Beckman-Coulter). 
Accessible DNA was amplified by PCR for 5 cycles, assessed for yield by qPCR, and amplified 
for an additional 7 cycles. Libraries were sequenced on a NextSeq 500 (Illumina).  
 
ATAC-seq Data Processing 
ATAC data from each sample was aligned using Bowtie2 (Langmead and Salzberg, 2012) after 
adaptor trimming using cutadapt (Martin, 2011) and PCR duplicates were removed using 
samtools (Li et al., 2009). Quadruplicate samples for each condition were used for peak calling 
by MACS2 (Zhang et al., 2008) with the parameters -q 0.001 --nomodel --shift 88 --extsize 177 to 
set an FDR threshold of 0.1% and account for average insert size. Coverage tracks were created 
using deeptools (Ramirez et al., 2014) using reads per genomic content (RPGC) normalization 
and visualized in Integrative Genomics Viewer (Thorvaldsdottir et al., 2013). To limit ATAC peak 
identification to transposase-accessible enhancers and exclude other accessible loci, ATAC 
peaks were filtered according to correspondence with H3K27ac- or H3K4me2-marked 
macrophage enhancers in resting or stimulated primary macrophages identified previously (Oishi 
et al., 2017). Enhancer overlap, overlap between conditions, and nearest gene annotation were 
performed using bedtools (Quinlan and Hall, 2010). Gene Ontology analysis of nearest genes for 
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each enhancer set was performed using the PANTHER database (Thomas et al., 2003) and 
sequence motif analysis was performed using HOMER (Heinz et al., 2010). Motif analysis for T0-
closed and LPS-opened enhancers was performed using the full set of unstimulated macrophage 
enhancers as sequence background, while motif analysis for T0-closed-in-LPS enhancers was 
performed using the full set of LPS-stimulated enhancers as sequence background. Enhancers 
were aligned to LXR ChIP-seq data from Oishi et al., 2017 using deeptools (Ramirez et al., 2014), 





For RNA-seq, macrophages were washed twice with cold PBS and lysed in TRIzol reagent 
(Thermo). RNA was isolated from the aqueous phase using RNeasy kits (Qiagen). RNA with RIN 
> 8 was subjected to poly-dT pulldown using magnetic beads (NEB) before preparation for RNA-
seq using RNA Ultra kits (NEB). Libraries were sequenced on a NextSeq 500 (Illumina) and reads 
were aligned to the mm10 transcriptome using HISAT2 (Kim et al., 2015) after adaptor trimming 
using cutadapt (Martin, 2011). Reads counts per gene for RefSeq genes were computed using 
featureCounts (Liao et al., 2014). Counts were normalized to reads per kilobase per million 
(RPKM) and processed for pairwise differential expression analysis of selected conditions using 
DESeq2 (Love et al., 2014) with a False Discovery Rate (FDR)-adjusted p-value cutoff of 0.05. 
Gene Ontology analysis was performed using the PANTHER database (Thomas et al., 2003). 
 
Measurement of Phosphatidylcholine Subspecies 
Phosphatidylcholine subspecies of BMDM were measured using infusion-based high-resolution 
mass spectrometry as described previously (Li et al., 2012) using a Triple TOF 5600 (AB-Sciex). 
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Lipids were extracted using the Bligh/Dyer method (Bligh and Dyer, 1959) after addition of internal 
standards and data were acquired on a Triple TOF 5600 operated in TOF mode at a resolution of 
35,000, electrospray source voltage of 5500 v on the Turbo B spray interface, declustering 
potential of 100 V, scanning from 100 to 1200 Da. Samples were infused at ~20 µL/min in a 
solution of 4:2:1 isopropanol:methanol:chloroform with 10 mM ammonium acetate with a Reliance 
autosampler (Sparck) operating in pressurized vessel mode. Quantitation was performed using 
MultiQuant (AB-Sciex). A window of +/- 5 mDa was used to identify PC species. Curves were 
calculated using 1/X weighting and were applied uniformly.  
 
Quantification and Statistical Analysis 
All data are presented as mean +/- SEM. In BMDM experiments, sample size (n) represents the 
number of individually differentiated primary macrophage cultures in each experiment. In 
peritonitis experiments, sample size (n) represents the number of individual mice in each 
experiment. The statistical parameters (n, mean, SEM, and statistical tests used) can be found 
within the figure legends and figures. For comparisons of 2 datasets, the Student’s t-test with 
Benjamini-Hochberg multiple testing correction was used to determine significance. For 
comparison of 3 or 4 datasets, one-way ANOVA with Tukey’s post-hoc test was used, except in 
the case of time-course data where two-way ANOVA with Sidak’s post-hoc test was used to 
determine significance. For RNA-seq, gene expression differences were evaluated by Wald test 
after linear model fitting using DESeq2 and genes significant at 5% FDR were considered to be 
differentially expressed. ATAC-seq peaks were identified using Model-Based Analysis of ChIP-
seq 2 (MACS2) software. Enhancer-gene distance distributions were compared using Kruskal-
Wallis nonparametric one-way ANOVA with Dunn post-hoc test. The criterion for significance was 
set at P < 0.05. No inclusion or exclusion criteria were used. No statistical method was used to 
determine whether the data met assumptions of the statistical approach. Statistical analyses were 
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performed using GraphPad Prism version 7.0.3 or R software with the indicated packages for 
sequencing data.  
 
Data and Software Availability 
The NCBI GEO accession numbers for high throughput sequencing data reported in this paper 
are: GSE110002, GSE109997, and GSE109998. Custom scripts for enhancer-promoter distance 
calculation are deposited at https://github.com/dgt2109/bio-script. 
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Mendelian Randomization on Large Datasets Suggests Association of 





Objective: Observational studies suggest that low-density lipoprotein-cholesterol (LDL-C), high-
density lipoprotein-cholesterol (HDL-C), and triglycerides (TG) are associated with coronary artery 
disease (CAD). Mendelian randomization (MR) has detected associations of LDL-C and TG, but 
not HDL-C, with CAD. The goal of this study is to perform MR using larger CAD and lipid trait 
variant datasets and contemporary pleiotropy adjustment approaches to determine whether HDL-
C is causally associated with CAD.   
 
Approach and Results: In MR of lipid traits in CAD using genome-wide significant variants, LDL-
C, HDL-C, and TG are associated with CAD in a multivariate model after removal of pleiotropic 
outliers. Adjustment for unmeasured directional pleiotropy attenuates the HDL-C and TG 
associations, but is associated with decreased precision, which limits power to detect associations 
of small magnitude. Thus, we develop a False Discovery Rate (FDR) approach to increase the 
number of instrumental variables for MR of lipid traits in CAD by 3-fold, which increases precision 
and decreases directional pleiotropy. MR on FDR-significant variants reveals associations with 
CAD for LDL-C (OR 1.37, 95%CI 1.29-1.44), HDL-C (OR 0.90, 95%CI 0.84-0.95), and TG (OR 
1.13, 95%CI 1.05-1.21), and each of these associations is robust to adjustment for unmeasured 
directional pleiotropy. 
 
Conclusions: MR of lipid traits in CAD on large datasets suggests that LDL-C, HDL-C, and TG 




Mendelian randomization (MR) is a strategy for assessment of the potential causal effect of an 
exposure on a disease outcome using observational genetic data such as the data collected from 
genome-wide association studies (GWAS) (Burgess et al., 2018). MR uses common genetic 
variants that have known effects on the exposure as instrumental variables to model the effect of 
the exposure on the disease outcome. Since individual genotypes can be viewed as random 
assignments, it has been suggested that MR can be used as an in silico approach for anticipating 
the results of clinical trials (Ference et al., 2016). One limitation of this approach is the tendency 
of individual genetic variants to affect multiple traits that each impact the disease outcome 
(Verbanck et al., 2018). This phenomenon is referred to as pleiotropy, and can lead to 
confounding of associations identified by MR. Several modified MR analyses, such as MR-
EGGER (Bowden et al., 2015) and multivariate MR-IVW (Burgess et al., 2013; Burgess and 
Thompson, 2015) have been developed to take pleiotropy and estimation uncertainty into 
account.  
 
The lipid traits low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol 
(HDL-C), and triglycerides (TG) have been linked with risk of coronary artery disease (CAD) 
through observational studies, and MR has recently been used to model causal contributions of 
these risk factors. In observational studies, high LDL-C is strongly associated with and causally 
implicated in CAD, but HDL-C and TG remain associated with CAD after correction for the effect 
of LDL-C (Emerging Risk Factors et al., 2009; Sarwar et al., 2007). HDL-C is inversely correlated 
with TG in human populations, reflecting the interchange of HDL cholesteryl esters with 
triglycerides carried in triglyceride-rich lipoproteins (Inazu et al., 1990). Thus, while low HDL-C 
and high TG have been linked with increased CAD, disentangling the relative contributions of 




In an early study, Voight et al. used MR to assess the independent contribution of HDL-C to CAD 
risk and found no effect for either a single HDL-raising variant in LIPG or 14 variants associated 
with HDL-C, but not LDL-C or TG (Voight et al., 2012). With the availability of larger lipid trait 
GWAS datasets, Do et al. used multivariate MR to model CAD effects of 185 variants associated 
with LDL-C, HDL-C, or TG and found that LDL-C and TG, but not HDL-C, are causally associated 
with CAD risk (Do et al., 2013). Because this study employed two-stage least squares regression 
for MR analysis, rather than an error-weighted approach, it may have been sensitive to the effect 
of outliers with high measurement errors. Indeed, analysis of this data using error-weighting or 
exclusion of pleiotropic variants associated with body mass index or blood pressure showed that 
HDL-C is associated with CAD by MR (Burgess et al., 2014). Multivariate MR of lipid traits in CAD 
using larger CAD datasets also showed that HDL-C is associated with CAD, but this association 
is attenuated after adjustment for unmeasured directional pleiotropy (White et al., 2016). This 
method decreases the precision of MR estimates (Zanetti et al., 2018) and may have limited the 
power of this study to detect an HDL-C association. Nevertheless, these results have been 
interpreted as indicating that HDL-C is not in the causal pathway of atherosclerosis (Benn and 
Nordestgaard, 2018; Dron and Hegele, 2016; McPherson and Tybjaerg-Hansen, 2016).  
 
Here, we use a larger CAD dataset, a larger set of instrumental variables, and statistical 
approaches to adjust for per-variant and global pleiotropy to evaluate the causal effects of lipid 
traits in CAD. LDL-C and HDL-C are independently associated with CAD in a multivariate MR 
analysis after exclusion of individual pleiotropic variants identified using the multivariate MR-
PRESSO outlier test, but only the LDL-C association remains in global pleiotropy-adjusted 
multivariate MR-EGGER analysis. Adjustment for unmeasured directional pleiotropy limits the 
precision of MR association coefficient estimates, so we use a larger set of False Discovery Rate 
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(FDR)-significant variants as instrumental variables to improve precision. FDR approaches have 
been shown to identify reproducible genetic associations (Nelson et al., 2017a), and we show that 
they improve statistical power of MR models. In multivariate MR on this larger dataset, LDL-C, 
HDL-C, and TG are independently associated with CAD and these associations are robust to 
adjustment for unmeasured directional pleiotropy using multivariate MR-EGGER. These results 
suggest that LDL-C, HDL-C, and TG are independent causal risk factors in CAD.  
 
Materials and Methods 
Datasets 
Data on lipid levels have been contributed by the Global Lipid Genetics Consortium (GLGC) and 
have been downloaded from http://csg.sph.umich.edu/willer/public/lipids2013/. Lipid trait effect 
sizes are in s.d. from inverse normal transformed residuals of lipids adjusted for covariates and 
population stratification as described in Willer et al. (Willer et al., 2013) Data on coronary artery 
disease / myocardial infarction have been contributed by the CARDIoGRAMplusC4D and UK 
Biobank CardioMetabolic Consortium CHD working group who used the UK Biobank Resource 
(application number 9922). Data have been downloaded from 
www.CARDIOGRAMPLUSC4D.org. CAD effect sizes are in log odds ratio adjusted for population 
stratification as described in Nelson et al. (Nelson et al., 2017a)  
 
Variant Selection 
For the MR analysis, we identified 185 variants that are genome-wide significant for at least one 
lipid trait as described in Willer et al. (Willer et al., 2013). Six variants missing lipid or CAD data 
were excluded from the analysis. We also selected a larger set of variants using an FDR-
controlled approach (Benjamini and Hochberg, 1995). For each variant, we calculated its FDR q-
value from its lipid trait summary statistics using the python model statsmodels (Seabold and 
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Perktold, 2010). For lipid trait variants significant at 5% FDR, we performed LD clumping using 
the software MRbase (Hemani et al., 2018) using a 1 Mb interval and an LD threshold of R2 < 
0.001. This procedure led to the identification of 680 variants, of which 667 had matched CAD 
data from the CARDIoGRAMplusC4D dataset. MR analysis was limited to common variants 
(minor allele frequency > 5%), since rare and low-frequency variants are associated with high 
measurement variability (Bowden et al., 2015). After exclusion of missing data and rare/low-
frequency variants, 174 genome-wide significant and 636 FDR-significant variants remained.  
 
The selected FDR-significant variants had FDR q-values < 0.05, which can be related to the first-
stage F-statistic; the F-statistic has been used as a measure of instrument strength (Pierce et al., 
2011). FDR q-values are larger than p-values by a multiple that depends on the total number of 
tests and the ranks of the selected tests (Storey, 2002); in our dataset, this multiple is always 
higher than 300. Thus, selected variants had a p-value < 0.05/300 = 1.67E-4 for the selected trait, 
which corresponds to a first-stage F-statistic of 12.9.  
 
Mendelian Randomization Analysis 
For MR analysis, we extracted lipid trait variant summary statistics (i.e. inverse normal 
transformed lipid trait effects) from the GLGC dataset and CAD risk variant summary statistics 
(i.e. log-odds ratios) from the CARDIoGRAMplusC4D dataset for the variant sets described 
above. In multivariate (MV) analyses, we oriented the variants with respect to a positive effect on 
the exposure of interest as described (Burgess and Thompson, 2015). We considered two types 
of multivariate MR analysis. One is multivariate MR, inverse-variance weighted (MVMR-IVW) 
(Burgess and Thompson, 2015), where we use multivariate regression to model log-odds ratios 
for CAD against the inverse normal transformed lipid trait effects and weight each variant by the 
standard error of its log-odds ratio for the outcome, while setting its intercept at zero. In a second 
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analysis, we used multivariate MR-EGGER (MVMR-EGGER) (Rees et al., 2017), where we also 
regress log-odds ratios for CAD against the inverse normal transformed lipid trait effects and 
weight each variant by the standard error of its log-odds ratio for the outcome. However, the 
intercept is estimated in MVMR-EGGER. For each model, I2 was calculated from H2 as described 
(Jackson et al., 2012). In addition, we also performed the multivariate MR-PRESSO (MVMR-
PRESSO) outlier test (Verbanck et al., 2018). The variants identified as pleiotropic outliers by 
MVMR-PRESSO were removed in the indicated MR analyses to produce more robust estimates.  
 
Mendelian Randomization Simulation 
For simulation of Mendelian randomization, genotypes for 200 variants were generated for 20,000 
individuals from a binomial distribution with minor allele frequency uniformly distributed on the 
interval from 0.05 to 0.5. The exposure and outcome data was generated as described (Burgess 
et al., 2016), except instrument strength was randomly generated from an exponential distribution 
to approximate the distribution of lipid trait effect sizes. Briefly, the data for exposure x and 
outcome y was generated according to the model xi = Σαkgik + ui + εXi and yi = βXxi + βUui + εYi, 
with αk ~ Exp(20), gik ~ Binom(2,qk), and qk ~ U(0.05,0.5) for k = 1,…,200 and ui ~ N(0,1), εXi ~ 
N(0,1), εYi ~ N(0,σY) independently for i = 1,…,20,000, with βX=0 or 1, βU=0.5, and varying values 
of σY. The exposure and outcome effect size for each variant was calculated in first-stage 
regression. The association between exposure and outcome was modeled across all variants 
meeting the specified exposure association significance threshold (either Bonferroni-significant 
or FDR-significant), with the intercept either fixed at 0 (for MR-IVW) or estimated as part of the 






Sensitivity Analyses for FDR-significant variants 
For MR on lipid traits with variants grouped by strength, 631 FDR-significant variants were used, 
and 5 pleiotropic variants identified by MVMR-PRESSO were excluded. For each lipid trait, first-
stage F-statistics were used to categorize variants as weak, intermediate-strength, or very strong, 
and multivariate MR was performed as above. Cochran’s Q statistics were calculated as 
described for each variant (Jackson et al., 2012), and per-variant heterogeneity p-values were 
computed by comparing Q statistics to a chi-square distribution with 1 degree of freedom as 
described (Bowden et al., 2018). For analysis of the effect of variant set size on HDL-C and TG 
association coefficients, the variants were ranked according to their most significant lipid trait 
effect q-value and subsets of incrementally increasing size were used for MVMR-IVW and MVMR-
EGGER analysis as described above. 
 
Code Availability 
R and python scripts are available at http://www.github.com/dgt2109/bio-script/. 
 
Results 
MR on Updated CAD Data and Identification of Pleiotropic Outliers 
We used the recent CARDIoGRAMplusC4D 2017 CAD data release comprising 71,602 cases 
and 123,504 controls to perform an updated two-sample lipid trait MR in CAD while removing 
pleiotropic variants identified by the MVMR-PRESSO outlier test (Verbanck et al., 2018). This 
approach tests for per-variant heterogeneity by comparing the effect size and measurement error 
for each variant with the distribution of effects predicted by the modeled association. We used 
185 variants identified as genome-wide significant for LDL-C, HDL-C, or TG, of which 174 were 
common variants for which data was available in GLGC and CARDIoGRAMplusC4D data 
repositories (Do et al., 2013). In MVMR-IVW analysis, LDL-C and HDL-C are associated with 
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CAD (Table 3.1). In this dataset, MVMR-PRESSO identifies two variants as pleiotropic outlier 
variants because these variants have large CAD effects that are not accounted for by lipid trait 
effects.  
 
LDL-C variants are associated with a large CAD effect with or without exclusion of the 2 pleiotropic 
variants (OR 1.51, 95%CI 1.38-1.66; Table 3.1, Figure 3.1A). HDL-C is associated with a 
moderate, protective effect on CAD risk in the MVMR-IVW model with or without exclusion of the 
2 pleiotropic variants (OR 0.86, 95%CI 0.78-0.95; Table 3.1, Figure 3.1B). MVMR-IVW does not 
detect an association between TG and CAD, with or without exclusion of the 2 pleiotropic variants, 
although there is a trend for a moderate deleterious effect (OR 1.11, 95%CI 0.99-1.25; Table 3.1, 
Figure 3.1C). In each case, there is a high degree of variation due to heterogeneity (I2), e.g. CAD 
effects inconsistent with the modeled lipid traits, suggesting potential for residual pleiotropic 
effects (I2 = 74-75%).  
 
The MVMR-IVW and MVMR-EGGER regressions are shown graphically in Figure 3.1; the shaded 
region indicates MVMR-IVW 95% confidence intervals. The effect of each lipid trait variant on lipid 
covariate-adjusted CAD is plotted with the variant oriented in the direction of increasing lipid trait 
(exposure) effect, so that points above the x-axis indicate deleterious effects and points below 
the x-axis indicate protective effects for variants increasing the lipid trait effect. Pleiotropic variants 
identified by MVMR-PRESSO are labeled with open circles. For each lipid trait, there are some 
variants with positive CAD effects and some variants with negative CAD effects because errors 
in CAD effect estimates are poorly controlled by this method, underscoring the importance of 





Table 3.1 MR of lipid traits in CAD using genome-wide significant variants 
 
MVMR-IVW MVMR-EGGER 
OR CI P I2 OR CI P I2 Int. Int. P 
LDL-C 1.51 1.38-1.66 1E-16 75% 1.67 1.50-1.87 2E-16 74% -5E-3 4E-3 
HDL-C 0.86 0.78-0.95 3E-3 75% 0.91 0.81-1.02 0.12 75% -3E-3 0.15 
TG 1.10 0.98-1.24 0.12 75% 1.05 0.92-1.21 0.45 75% 3E-3 0.21 
   
 
MVMR-IVW, MR-PRESSO-adjusted MVMR-EGGER, MR-PRESSO-adjusted 
OR CI P I2 OR CI P I2 Int. Int. P 
LDL-C 1.48 1.35-1.62 1E-14 75% 1.63 1.46-1.82 7E-15 73% -0.01 0.01 
HDL-C 0.86 0.78-0.95 2E-3 75% 0.91 0.81-1.02 0.12 74% -3E-3 0.14 
TG 1.11 0.99-1.25 0.08 74% 1.06 0.93-1.21 0.41 74% 3E-3 0.14 
 
All analyses were multivariate regressions of CAD on LDL-C, HDL-C, and TG.  
MVMR-IVW: multivariate Mendelian randomization, inverse-variance weighted 
MVMR-EGGER: multivariate Mendelian randomization-Egger regression  
OR: odds ratio 


































Figure 3.1 MR of lipid traits in CAD using genome-wide significant variants 
Points represent genome-wide significant common lipid trait variants without missing data in 
GLGC and CARDIoGRAMplusC4D datasets. Pleiotropic variants identified by MVMR-PRESSO 
are shown as open circles. Black dashed lines represent MVMR-IVW regression lines and grey 
shaded areas represent 95% confidence intervals; red dashed lines represent MVMR-EGGER 
regression lines.  
(A) Plot of LDL-C effect size in standard deviation units against HDL-C- and TG-adjusted CAD 
risk.  
(B) Plot of HDL-C effect size in standard deviation units against LDL-C- and TG-adjusted CAD 
risk. 





Effect of Adjustment for Unmeasured Directional Pleiotropy 
The MR-EGGER approach evaluates and adjusts for the presence of unmeasured directional 
pleiotropy in an MR model based on the estimated intercept of the exposure-outcome association 
(Bowden et al., 2015). The MR-EGGER regression intercept can be interpreted as the model’s 
prediction of an outcome effect in the absence of an exposure effect, e.g. directional pleiotropy. 
A multivariate extension of this method has been recently developed (Rees et al., 2017). We used 
MVMR-EGGER to develop pleiotropy-adjusted coefficient estimates for MR of lipid traits in CAD. 
In this model, LDL-C is associated with CAD (OR 1.63, 95%CI 1.46-1.82; Table 3.1; Figure 3.1A), 
but the HDL-C and TG associations are attenuated (HDL-C OR 0.91, 95%CI 0.81-1.02; TG OR 
1.06, 95%CI 0.93-1.21; Table 3.1, Figure 3.1B-C). In spite of this attenuation, the MVMR-EGGER 
intercept test for directional pleiotropy is null for HDL-C and TG (Table 3.1). In contrast, the 
intercept test indicates directional pleiotropy for LDL-C, and adjustment for pleiotropy increases 
the magnitude of the association of LDL-C with CAD (Table 3.1). However, MVMR-EGGER 
regression results in wider confidence intervals than the MVMR-IVW approach for each lipid trait 
(Table 1), which may limit power to detect associations of small magnitude, and there is a high 
degree of variation due to heterogeneity (I2 = 73-74%).   
 
Previous studies have described improvements in statistical power of MR related to the use of 
multiple variants as instrumental variables (Palmer et al., 2012). A recent study applying the FDR 
procedure to GWAS has empirically validated variants identified by FDR significance thresholds 
by replication in larger samples (Nelson et al., 2017a), suggesting that an FDR-controlled 
approach for increasing the number of variants available for MR may capture additional genetic 
associations. In addition, Willer et al. found that the GLGC lipid trait dataset contains an excess 
of variants with marginal p-values that were directionally concordant in non-overlapping samples 
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for LDL-C, HDL-C, and TG, suggesting that some variants that impact lipid levels are missed at 
stringent genome-wide significance thresholds (Willer et al., 2013).  
 
We considered whether selecting variants for MR according to an FDR significance threshold, 
rather than the more stringent Bonferroni criteria, would increase statistical power and precision 
in MR and tested this approach in simulated MR experiments. Using a Monte Carlo method, we 
simulated 200 variants in 20,000 individuals and modeled the association between exposure and 
outcome variables by MR in the presence of confounding and measurement error. Using FDR-
significant variants as instrumental variables has minimal effect on the MR-IVW analysis, which 
maintains >80% power as measurement error is increased (Figure 3.2A, C). The MR-EGGER 
model leads to greater coefficient estimate variability and reduced power compared to MR-IVW 
(Figure 3.2B, D). For the MR-EGGER model, using FDR-significant variants decreases coefficient 
estimate variability and increases power of MR-EGGER by 50-60%. There is no adverse effect 






































Figure 3.2 Modeled FDR-significant variants improve precision and power of MR-EGGER 
 MR analysis was simulated using 200 variants in 20,000 individuals to model a true association 
(A-D) or a null association (E-F) between exposure and outcome variables in the presence of 
confounding.  
(A-B) Beta coefficient estimates across 100 trials for observational associations, MR-IVW (A), or 
MR-EGGER (B) with varying levels of measurement error.  
(C-D) Fraction of trials detecting the true association, e.g. statistical power, in observational 
associations, MR-IVW (C), or MR-EGGER (D).  
(E-F) Fraction of trials detecting a false positive association, e.g. type I error, in observational 





MR on FDR-significant Variants 
To increase the statistical power and precision of MR in lipid traits in CAD, we used the FDR-
controlled approach to identify lipid trait variants to use as instrumental variables. At 5% FDR, 
636 common variants are associated with LDL-C, HDL-C, or TG with lipid and CAD data available, 
increasing the number of instrumental variables available for MR analysis by over 3-fold. In 
MVMR-IVW on these variants, LDL-C is associated with a large effect on CAD with or without 
exclusion of 5 pleiotropic variants identified by MVMR-PRESSO (OR 1.37, 95%CI 1.29-1.46; 
Table 3.2, Figure 3.3A). HDL-C is associated with CAD by MVMR-IVW, and the association 
remains robust after exclusion of the 5 pleiotropic variants (OR 0.90, 95%CI 0.84-0.95; Table 3.2, 
Figure 3.3B). TG is also associated with CAD by MVMR-IVW with or without exclusion of the 5 
pleiotropic variants (OR 1.13, 95%CI 1.05-1.21; Table 3.2, Figure 3.3C). The degree of variation 
due to heterogeneity is high in MVMR-IVW of FDR-significant variants (I2 = 61%), but 
heterogeneity is reduced by removal of the 5 pleiotropic variants (I2 = 51%).  
 
Adjustment for pleiotropy using MVMR-EGGER increases the magnitude of the coefficient for the 
LDL-C association moderately (OR 1.48, 95%CI 1.37-1.60; Table 3.2, Figure 3.3A). After 
inclusion of FDR-significant variants, the MVMR-EGGER associations for HDL-C and TG are 
highly concordant with the results of MVMR-IVW analysis, albeit with decreased precision (HDL-
C OR 0.91, 95%CI 0.84-0.98; TG OR 1.10, 95%CI 1.00-1.21; Table 3.2, Figure 3.3B-C). As a 
result, the regression lines for MVMR-IVW and MVMR-EGGER are nearly superimposed in MR 
of FDR-significant variants for HDL-C and TG (Figure 3.3B-C). The MVMR-EGGER intercept test 
is positive for LDL-C, consistent with the increase in the coefficient estimate after adjustment for 
pleiotropy (Table 3.2). The MVMR-EGGER intercept tests for the HDL-C and TG associations are 
null (Table 3.2). The degree of variation due to heterogeneity is moderate for each MVMR-
EGGER model (I2 = 50-51%).  
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Table 3.2 MR of lipid traits in CAD using FDR-significant variants 
 
MVMR-IVW MVMR-EGGER 
OR CI P I2 OR CI P I2 Int. Int. P 
LDL-C 1.37 1.29-1.46 4E-22 61% 1.48 1.37-1.60 9E-22 60% -3E-3 1E-3 
HDL-C 0.89 0.84-0.95 9E-4 61% 0.90 0.83-0.99 0.02 61% -4E-4 0.63 
TG 1.12 1.04-1.22 5E-3 61% 1.10 0.99-1.22 0.07 61% 7E-4 0.50 
   
 
MVMR-IVW, MR-PRESSO-adjusted MVMR-EGGER, MR-PRESSO-adjusted 
OR CI P I2 OR CI P I2 Int. Int. P 
LDL-C 1.37 1.29-1.44 2E-25 51% 1.45 1.35-1.56 2E-23 50% -2E-3 0.01 
HDL-C 0.90 0.84-0.95 3E-4 51% 0.91 0.84-0.98 0.01 51% -5E-4 0.58 
TG 1.13 1.05-1.21 2E-3 51% 1.10 1.00-1.21 0.05 51% 7E-4 0.41 
 
All analyses were multivariate regressions of CAD on LDL-C, HDL-C, and TG.  
MVMR-IVW: multivariate Mendelian randomization, inverse-variance weighted 
MVMR-EGGER: multivariate Mendelian randomization-Egger regression  
OR: odds ratio 


































Figure 3.3 MR of lipid traits in CAD using FDR-significant variants 
Points represent FDR-significant common lipid trait variants without missing data in GLGC and 
CARDIoGRAMplusC4D datasets. Pleiotropic variants identified by MVMR-PRESSO are shown 
as open circles; one pleiotropic variant, rs2315065, is omitted due to a large CAD effect that falls 
outside the y-axis limits. Black dashed lines represent MVMR-IVW regression lines and grey 
shaded areas represent 95% confidence intervals; red dashed lines represent MVMR-EGGER 
regression lines.  
(A) Plot of LDL-C effect size in standard deviation units against HDL-C- and TG-adjusted CAD 
risk.  
(B) Plot of HDL-C effect size in standard deviation units against LDL-C- and TG-adjusted CAD 
risk.  





MR of Lipid Traits in CAD by Instrument Strength 
Lipid trait effect sizes for the set of FDR-significant variants are on average smaller in magnitude 
than those of genome-wide significant variants. The presence of weak instruments (e.g. first-stage 
F-statistic < 10) can lead to bias in the MR effect estimate, particularly when samples for the 
exposure and outcome datasets overlap (Burgess et al., 2016; Pierce et al., 2011). MR of lipid 
traits in CAD has little sample overlap due to the low proportion of CAD cases that are used for 
lipid GWAS (approximately 5%), and as a result weak instrument bias tends to attenuate lipid trait 
associations (Burgess et al., 2016). Selection of variants at an FDR of 5% controls the selected 
trait first-stage F-statistics at values greater than 12.9 in the lipid trait dataset, as described in 
Materials and Methods, limiting the potential for weak instrument bias. However, we modeled all 
lipid trait effects for variants associated with one or more lipid traits in a multivariate analysis, so 
some variants are associated with strong effects on one lipid trait and weak effects on the others. 
Thus, as a sensitivity analysis, we performed MVMR-IVW with groups of variants binned by 
instrument strength for each lipid trait.  
 
In each case, weak variants (F<10) do not predict any association with CAD and have minimal 
impact on the effect estimates (Figure 3.4A). Associations for all three lipid traits are driven by 
variants of intermediate strength (10<F<100), which capture the magnitude of the CAD 
association accurately in each case (Figure 3.4A). LDL-C variants of very high strength (F>100) 
are associated with a larger OR for CAD per unit change in LDL-C than intermediate-strength 
variants, suggesting effect heterogeneity. HDL-C and TG variants of very high strength are not 





We investigated the cause of effect estimate heterogeneity between sets of variants grouped by 
instrument strength by calculating the per-variant heterogeneity statistic Cochran’s Q for each 
variant in the overall MVMR-IVW model. For HDL-C, very strong variants have higher measures 
of per-variant heterogeneity by Cochran’s Q than intermediate-strength or weak variants (Figure 
3.4C) and are more likely to test positive for heterogeneity when Q is compared to the chi-square 
distribution (Figure 3.4F). Several of these variants encode genes involved in lipoprotein 
remodeling, such as Cetp, Lipc, and Lpl, suggesting that variants involved in these processes 
may have pleiotropic effects on CAD through mechanisms distinct from their HDL-C effect. In 
contrast, per-variant heterogeneity measures of LDL-C and TG variants do not distinguish 






























Figure 3.4 MR of lipid traits in CAD by instrument strength 
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Figure 3.4 MR of lipid traits in CAD by instrument strength 
FDR-significant lipid trait variants were divided into classes based on first-stage F-statistic. 
MVMR-IVW confidence intervals and heterogeneity statistics were calculated.  
(A) Forest plot of MVMR-IVW confidence intervals for LDL-C, HDL-C, and TG by instrument 
strength.  
(B-D) Cochran’s Q statistics for variants in each class for LDL-C (B), HDL-C (C), and TG (D) were 
calculated. Q statistics for variants of very high strength were compared to Q statistics of 
intermediate-strength and weak variants by Kruskal-Wallis nonparametric ANOVA with Dunn’s 
post-hoc test.  
(E-G) Variants in each instrument strength class for LDL-C (E), HDL-C (F), and TG (G) were 
tested for heterogeneity by comparing the Q statistic for each variant with the chi-square 
distribution with one degree of freedom, and the percentage of heterogeneous variants in each 




Effect of FDR-significant Variants on MR of HDL-C and TG in CAD 
As a sensitivity analysis, we performed multivariate MR of LDL-C, HDL-C, and TG in CAD while 
varying the number of variants used as instrumental variables. MVMR-IVW coefficient estimates 
for HDL-C stabilize after inclusion of >150 variants, and MVMR-EGGER coefficient estimates 
converge with MVMR-IVW estimates after inclusion of >500 variants (Figure 3.5A). Inclusion of 
additional variants does not attenuate the coefficient estimate in either case, suggesting that the 
5% of false discoveries lacking true CAD associations are less influential than the 95% of true 
associations. Inclusion of additional variants decreases the standard error of HDL-C coefficient 
estimates, and 300 variants are required to achieve sufficient precision to detect the final MVMR-
EGGER association (Figure 3.5B). For TG, inclusion of additional variants leads to convergence 
of MVMR-IVW and MVMR-EGGER coefficient estimates (Figure 3.5C) and increases coefficient 
estimate precision; in this case, almost 600 variants are required to achieve sufficient precision 
to detect the final MVMR-EGGER association (Figure 3.5D).  
 
Inclusion of FDR-significant variants decreases the degree of variation due to heterogeneity (I2) 
in the multivariate lipid trait model estimating the HDL-C association (Figure 3.6A). In a similar 
manner, the MVMR-EGGER intercept estimate for the HDL-C association is attenuated 
progressively with inclusion of additional variants and is close to 0 at >500 variants (Figure 3.6B). 
In a similar manner, inclusion of additional variants decreases the degree of variation due to 
heterogeneity (I2) and the intercept estimate in the multivariate model estimating the TG 




































Figure 3.5: Coefficient estimates and precision in variant sets of varying size 
Variants were ordered according to first-stage lipid trait effect q-value and subsets of the most 
significant variants were used for MVMR-IVW and MVMR-EGGER analysis.  
(A) Effect of variant set size on coefficient estimate for HDL-C.  
(B) Effect of variant set size on coefficient estimate standard error (SE) for HDL-C. Dashed line 
represents precision required to detect the final MVMR-EGGER HDL-C association.  
(C) Effect of variant set size on coefficient estimate for TG.  
(D) Effect of variant set size on coefficient estimate standard error for TG. Dashed line represents 




































Figure 3.6: Heterogeneity statistic I2 and MR-EGGER intercept estimate by variant set size 
Variants were ordered according to first-stage lipid trait effect q-value and subsets of the most 
significant variants were used for MVMR-IVW and MVMR-EGGER analysis.  
(A) Effect of variant set size on heterogeneity statistic I2 for multivariate model estimating HDL-C 
association.  
(B) Effect of variant set size on MVMR-EGGER intercept estimate for multivariate model 
estimating HDL-C association. Solid line represents intercept = 0.  
(C) Effect of variant set size on heterogeneity statistic I2 for multivariate model estimating TG 
association.  
(D) Effect of variant set size on MVMR-EGGER intercept estimate for multivariate model 





The present MR analysis demonstrates associations of LDL-C, HDL-C, and TG with CAD using 
multivariate MR analysis with pleiotropy adjustment and a larger set of instrumental variables, 
which led to improved precision and attenuation of directional pleiotropy. The LDL-C association 
was robust in all analyses, while HDL-C and TG associations require large sets of variants to 
overcome effect heterogeneity and precision issues. These results provide continued support for 
a central role of LDL-C in CAD and additional evidence for a causal role of HDL-C and TG using 
large datasets and contemporary pleiotropy adjustment approaches.  
 
Before use of error-weighted and pleiotropy-adjusted methods for MR had been widely adopted, 
several studies using single instrument models, polygenic risk scores, and multivariate lipid-
adjusted models did not detect an association between HDL-C and CAD (Do et al., 2013; Voight 
et al., 2012). While some MR models support an association between HDL-C and lipid covariate-
adjusted CAD, adjustment for unmeasured directional pleiotropy attenuates this association 
(Burgess et al., 2014; White et al., 2016). The methods used for pleiotropy adjustment tend to 
decrease estimate precision (Zanetti et al., 2018) and consequently decrease statistical power, 
as we demonstrate in simulated MR experiments. We report that in large CAD datasets, HDL-C 
and TG are independently associated with CAD, and these effects are robust to adjustment for 
pleiotropy when a large set of instrumental variables is used to increase effect estimate precision. 
For this purpose, we employ an FDR-controlled approach to lipid trait variant selection, a strategy 
that improves the power of pleiotropy-adjusted models in MR simulations. We demonstrate that 
inclusion of these variants attenuates effect estimate standard error and unmeasured directional 
pleiotropy. Consequently, we find that LDL-C, HDL-C, and TG are independently associated with 




The HDL-C association we detected is consistent with but smaller in magnitude than the effect 
observed in observational studies (Emerging Risk Factors et al., 2009). A recent study using a 
different MR methodology, MR-robust adjusted profile score (MR-RAPS), also detected an 
association of HDL-C with CAD risk by MR (Zhao et al., 2018). In this approach, a Bayesian model 
accounts for per-variant and global pleiotropy, analogous to our use of MVMR-PRESSO and 
MVMR-EGGER for this purpose. MR-RAPS detects a heterogeneous, independent HDL-C 
association using an expanded set of variants as instrumental variables, consistent with our 
results, although only univariate analyses were reported. Another recently proposed approach for 
modeling genetic causality distinct from MR does not detect an HDL-C association (O'Connor and 
Price, 2018), but this study only used UK BioBank CAD cases. In the 2017 interim release, this 
represented 17,283 cases (Nelson et al., 2017a), or about one fourth of the cases we used to 
model CAD effects. Likewise, the first multivariate lipid trait MR study did not detect an HDL-C 
association with 22,233 CAD cases, while a later study using 63,158 CAD cases reported an 
HDL-C association by MVMR-IVW (Do et al., 2013; White et al., 2016). CAD sample size is a key 
determinant of measurement error, and we show that measurement error is a key determinant of 
statistical power in MR, especially for MR-EGGER.  
 
The strong independent inverse relationship between HDL-C and CAD risk in observational 
studies led to the “HDL hypothesis” that increasing HDL-C would consistently and proportionately 
reduce CAD risk (Rader and Hovingh, 2014). Recently, the failure or early termination of several 
clinical trials involving agents that increase HDL-C, most notably trials with some cholesteryl ester 
transfer protein inhibitors (Barter et al., 2007; Lincoff et al., 2017; Schwartz et al., 2012), along 
with MR studies that led to the inference that HDL-C was not in the causal pathway of 
atherosclerosis (Do et al., 2013; Voight et al., 2012), have resulted in a widespread rejection of 
this hypothesis (Benn and Nordestgaard, 2018; Dron and Hegele, 2016; McPherson and 
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Tybjaerg-Hansen, 2016). While our findings do not refute the disappointing clinical trials data, 
they indicate that inferences concerning clinical efficacy based on the lack of association between 
HDL-C and CAD in earlier MR studies may not be valid.  
 
The limitations of our study are the use of instrumental variables with weaker lipid trait 
associations than genome-wide significant variants and the potential for unmeasured horizontal 
pleiotropy in CAD effects of lipid trait variants. On the one hand, instrumental variable analyses 
using many weak instruments may be biased toward the null when there is little sample overlap 
between exposure and outcome datasets (Burgess et al., 2016). On the other hand, we show that 
selection at the FDR-significance threshold controls instrument strength at an acceptable level 
and that weak instruments do not strongly influence the observed associations. Unmeasured 
horizontal pleiotropy may complicate our analysis, particularly because of the association of CAD 
with other metabolic traits that also vary at several HDL-C loci. However, we modeled HDL-C 
associations in multivariate models accounting for the other major lipid traits and used multiple 
statistical approaches to mitigate effects of per-variant and global pleiotropy. Moreover, a previous 
MR study that excluded variants associated with other metabolic traits also detected an HDL-C 
association with CAD (Burgess et al., 2014). 
 
These issues, and the limitations in MR precision our study addresses, highlight challenges to the 
utility of MR in predicting the results of clinical trials. This point was underscored by the recent 
success of an inhibitor of interleukin-1β despite MR analysis indicating that antagonists of 
interleukin-1 were associated with increased CAD risk (Interleukin 1 Genetics, 2015; Ridker et al., 
2017), which led to questions concerning the efficacy of the intervention (Welsh et al., 2017). 
Thus, while our analysis provides supportive evidence for a causal association between HDL-C 
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and CAD, it should be interpreted in the context of the results of clinical trials, biochemical, and 
mechanistic studies.  
 
Highlights 
• Mendelian randomization of lipid traits in CAD is refined using larger CAD datasets, two 
pleiotropy adjustment approaches, and FDR-significant lipid trait variants to improve 
precision and reduce directional pleiotropy 
• LDL-C, HDL-C, and TG are associated with CAD by multivariate Mendelian 
randomization, and these associations are robust to adjustment for pleiotropy when large 
datasets are used  
• Some therapies targeting HDL-C, TG, or correlated atherogenic lipoprotein functions may 
have clinical utility in prevention of CAD events 
 
Sources of Funding 







The cholesterol efflux and immunoregulatory activities of LXR agonists and HDL have led to their 
evaluation as targets for ASCVD therapies to complement the beneficial effects of LDL-lowering 
agents (Rader and Hovingh, 2014; Schulman, 2017). In the case of LXR agonists, the lipogenic 
effects of LXR transactivation in liver limit clinical translation (Schultz et al., 2000). To circumvent 
this issue, several selective or targeted LXR agonists have been developed with the aim of 
producing anti-atherogenic effects or anti-inflammatory effects without hepatotoxic effects (Chao 
et al., 2008; Nomura et al., 2015; Tang et al., 2016; Zhang et al., 2015). This suggests the 
importance of understanding the mechanisms and physiological context of LXR’s anti-atherogenic 
and anti-inflammatory effects, but there have been conflicting reports on these issues (Schulman, 
2017). Transactivation of the atheroprotective cholesterol efflux transporters by LXR is likely to 
play a partial role in anti-atherogenic effects of LXR agonists in mice (Westerterp et al., 2013). In 
addition, several studies suggest a major role of LXR’s anti-inflammatory function, highlighting 
this activity as a potential target for selective agonists (Kappus et al., 2014; Zhang et al., 2012).  
 
However, recent studies have implicated transactivation of LXR targets in LXR’s anti-inflammatory 
effects, raising doubt about the feasibility of inflammatory gene repression by selective LXR 
agonists that promote only LXR repression. Leukocyte-targeted agonists represent an alternative 
approach, but reticuloendothelial uptake of these agents leads to broad biodistribution and control 
of potential toxicity remains a key concern (Tang et al., 2016). More generally, the efficacy of 
targeting cholesterol efflux to HDL as a beneficial anti-atherogenic function in humans has been 
questioned as a result of several studies that did not detect a causal association between HDL-C 






Figure 4.1 Schematic of cis-repression and cholesterol efflux mechanisms for anti-inflammatory 




The present studies aim to elucidate the mechanism of LXR’s anti-inflammatory effect and the 
question of causality in the association between HDL-C and CAD, with the goal of establishing 
the feasibility of targeting these pathways in ASCVD. In Chapter 2, we showed that anti-
inflammatory effects of LXR agonists are a result of both cholesterol efflux-dependent effects and 
a direct cis-repression pathway that involves binding of LXR and chromatin closure at 
inflammatory gene enhancers (Figure 4.1). Furthermore, we showed that LXR cis-repression 
targets neutrophil migration genes such as Itgb2 and attenuates neutrophil migration during sterile 
peritonitis. In a similar manner, LXR activation suppresses integrin gene expression in 
atherosclerosis.  
 
In Chapter 3, we addressed the question of whether HDL-C is causally associated with CAD by 
modeling the association of lipid trait variants with CAD by MR in large datasets. In particular, we 
defined a new approach for selection of instrumental variables based on control of the FDR and 
show that this improves MR precision and statistical power, especially when associations are 
adjusted for effects of variants that modify CAD risk via multiple pathways. Thus, we develop 
precise, pleiotropy-adjusted estimates of the effects of lipid traits on CAD risk and show that LDL-
C, HDL-C, and TG are associated with CAD risk by MR (Figure 4.2), although the effect estimates 
for HDL-C and TG are moderately smaller than observational associations. These results tend to 
refute a widely held concept that HDL is not in the causal pathway of atherosclerosis (Rader and 
Hovingh, 2014) and suggest that some agents targeting either HDL-C or TG may be protective in 
CAD.  
 
In summary, our studies highlight a novel cis-repressive activity of LXR with beneficial anti-
inflammatory effects in mouse models of peritonitis and atherosclerosis and reveal a protective 
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association between HDL-C and CAD by MR, suggesting a causal protective effect of HDL and 
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